{"content":"<li class=\"n-box-item date-title\" data-end=\"1553572799\" data-start=\"1553486400\" data-txt=\"Monday, December 23, 2019\">Monday, March 25, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3445552\" data-ts=\"1553554349\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KNDI\" target=\"_blank\">KNDI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445552-kandi-technologies-shareholders-file-to-offer-up-to-7_64m-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kandi Technologies shareholders file to offer up to 7.64M shares</a></h4><ul>   <li>Kandi Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a>) is <font color=\"red\">1.8% lower</font> after hours following a <a href=\"https://seekingalpha.com/filing/4417341\" target=\"_blank\">prospectus filing</a> for 7.64M shares to be sold by a selling stockholder.</li>    <li>The shares were issued to the selling stockholders in connection with the company's purchase by Jinhua An Kao Power Technology and SC Autosports.</li>    <li>The total holding in the prospectus amounts to a 13.7% stake in the company.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3445552\" data-linked=\"Kandi Technologies shareholders file to offer up to 7.64M shares\" data-tweet=\"$KNDI - Kandi Technologies shareholders file to offer up to 7.64M shares https://seekingalpha.com/news/3445552-kandi-technologies-shareholders-file-to-offer-up-to-7_64m-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3445552-kandi-technologies-shareholders-file-to-offer-up-to-7_64m-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445550\" data-ts=\"1553553355\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKTX\" target=\"_blank\">AKTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445550-akari-holder-aspire-capital-files-to-sell-500m-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akari holder Aspire Capital files to sell 500M shares</a></h4><ul>   <li>Akari Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics, Plc'>AKTX</a>) has filed a prospectus for the sale by holder Aspire Capital Fund of <a href=\"https://seekingalpha.com/filing/4417031\" target=\"_blank\">500M ordinary shares</a>.</li>    <li><a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics, Plc'>AKTX</a> is <font color=\"red\">off 1.6%</font> after hours; shares <font color=\"red\">fell 10%</font> during the regular session.</li>    <li>It relates to the sale of 445M ordinary shares (with each ADS representing 100 ordinary shares) that it might issue to Aspire Capital in the future as part of a securities purchase agreement they reached on Sept. 26.</li>    <li>It also relates to the sale of 550,000 ADS, consisting of 300,000 that can be exchanged for 30M ordinary shares, which were issued to the selling stockholder, and 250,000 ADS sold to the selling stockholder for $0.02/share.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3445550\" data-linked=\"Akari holder Aspire Capital files to sell 500M shares\" data-tweet=\"$AKTX - Akari holder Aspire Capital files to sell 500M shares https://seekingalpha.com/news/3445550-akari-holder-aspire-capital-files-to-sell-500m-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3445550-akari-holder-aspire-capital-files-to-sell-500m-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445547\" data-ts=\"1553552267\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445547-inovioplus-5-cantor-signs-on-new-bull\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Inovio +5% as Cantor signs on as new bull</a></h4><ul>   <li>Inovio Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/INO' title='Inovio Pharmaceuticals, Inc.'>INO</a>) is <font color=\"green\">up 5%</font> after hours following an initiation at Overweight by Cantor Fitzgerald.</li>    <li>There's a \"large and growing need\" for non-invasive treatment of HPV-related cervical dysplasia, analyst Charles Duncan notes. Phase 3 studies of VGX-3100 offer a \"major value driver\" over the next 12-18 months, and Inovio would also likely see a royalty stream if partner AstraZeneca/MedImmune (NYSE:<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca PLC'>AZN</a>) gets approval for MEDI0457 (which should see Phase 3 data in the second half). (h/t Bloomberg)</li>    <li>Duncan has a price target of $12, implying 231% upside from today's close of $3.62.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3445547\" data-linked=\"Inovio +5% as Cantor signs on as new bull\" data-tweet=\"$INO $AZN $AZNCF - Inovio +5% as Cantor signs on as new bull https://seekingalpha.com/news/3445547-inovioplus-5-cantor-signs-on-new-bull?source=tweet\" data-url=\"https://seekingalpha.com/news/3445547-inovioplus-5-cantor-signs-on-new-bull\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445539\" data-ts=\"1553549246\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445539-lob-bold-cvia-and-zumz-among-notable-after-hours-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LOB, BOLD, CVIA and ZUMZ among notable after hours movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/LOB' title='Live Oak Bancshares, Inc.'>LOB</a> <font color=\"green\">+6.74%</font>. <a href='https://seekingalpha.com/symbol/BOLD' title='Audentes Therapeutics, Inc.'>BOLD</a> <font color=\"green\">+5.0%</font>. <a href='https://seekingalpha.com/symbol/INO' title='Inovio Pharmaceuticals, Inc.'>INO</a> <font color=\"green\">+4.97%</font>. <a href='https://seekingalpha.com/symbol/ATNX' title='Athenex, Inc.'>ATNX</a> <font color=\"green\">+4.17%</font>. <a href='https://seekingalpha.com/symbol/ADMS' title='Adamas Pharmaceuticals, Inc.'>ADMS</a> <font color=\"green\">+3.70%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/CVIA' title='Covia Holdings Corporation'>CVIA</a> <font color=\"red\">-8.76%</font>. <a href='https://seekingalpha.com/symbol/ZUMZ' title='Zumiez Inc.'>ZUMZ</a> <font color=\"red\">-4.99%</font>. <a href='https://seekingalpha.com/symbol/SENS' title='Senseonics Holdings, Inc.'>SENS</a> <font color=\"red\">-3.83%</font>. <a href='https://seekingalpha.com/symbol/MYOK' title='MyoKardia, Inc.'>MYOK</a> <font color=\"red\">-3.8%</font>. <a href='https://seekingalpha.com/symbol/HZO' title='MarineMax, Inc.'>HZO</a> <font color=\"red\">-3.68%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445539\" data-linked=\"LOB, BOLD, CVIA and ZUMZ among notable after hours movers\" data-tweet=\"$LOB $BOLD $INO - LOB, BOLD, CVIA and ZUMZ among notable after hours movers https://seekingalpha.com/news/3445539-lob-bold-cvia-and-zumz-among-notable-after-hours-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3445539-lob-bold-cvia-and-zumz-among-notable-after-hours-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445511\" data-ts=\"1553545565\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTMX\" target=\"_blank\">CTMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445511-cytomx-finance-chief-bids-adieu\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CytomX finance chief bids adieu</a></h4><ul><li>CytomX Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CTMX' title='CytomX Therapeutics, Inc.'>CTMX</a>) <a href=\"https://seekingalpha.com/pr/17454301-cytomx-therapeutics-announces-transition-chief-financial-officer\" target=\"_blank\">announces </a>that CFO Debanjan Ray will resign on May 15 to accept the CEO job at an unnamed biotech startup. A search for a successor has been initiated.</li><li>Shares are down <font color=\"red\">2%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445511\" data-linked=\"CytomX finance chief bids adieu\" data-tweet=\"$CTMX - CytomX finance chief bids adieu https://seekingalpha.com/news/3445511-cytomx-finance-chief-bids-adieu?source=tweet\" data-url=\"https://seekingalpha.com/news/3445511-cytomx-finance-chief-bids-adieu\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445500\" data-ts=\"1553544951\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALDX\" target=\"_blank\">ALDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445500-aldeyra-sets-conference-call-on-reproxalap-data-in-allergic-conjunctivitis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aldeyra sets conference call on reproxalap data in allergic conjunctivitis</a></h4><ul><li>Aldeyra Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ALDX' title='Aldeyra Therapeutics, Inc.'>ALDX</a>) will host a <a href=\"https://seekingalpha.com/pr/17454283-aldeyra-therapeutics-schedules-webcast-conference-call-announce-top-line-results-phase-3\" target=\"_blank\">conference call</a> tomorrow, March 26, at 8:00 am ET to discuss <a href=\"https://seekingalpha.com/news/3438604-aldeyra-5-percent-ahead-key-data-readout-reproxalap-allergic-conjunctivitis\" target=\"_blank\">topline data</a> from the Phase 3 <a href=\"https://clinicaltrials.gov/ct2/show/NCT03494504?titles=alleviate&amp;lead=aldeyra&amp;rank=1\" target=\"_blank\">ALLEVIATE </a>study evaluating topical ocular reproxalap in patients with allergic conjunctivitis.</li><li>Shares are up <font color=\"green\">5%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445500\" data-linked=\"Aldeyra sets conference call on reproxalap data in allergic conjunctivitis\" data-tweet=\"$ALDX - Aldeyra sets conference call on reproxalap data in allergic conjunctivitis https://seekingalpha.com/news/3445500-aldeyra-sets-conference-call-on-reproxalap-data-in-allergic-conjunctivitis?source=tweet\" data-url=\"https://seekingalpha.com/news/3445500-aldeyra-sets-conference-call-on-reproxalap-data-in-allergic-conjunctivitis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445493\" data-ts=\"1553544555\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KOOL\" target=\"_blank\">KOOL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445493-cesca-therapeutics-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cesca Therapeutics misses on revenue</a></h4><ul><li>Cesca Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/KOOL' title='Cesca Therapeutics Inc.'>KOOL</a>): FY GAAP EPS of -$2.16.</li><li>Revenue of $9.67M (-24.3% Y/Y) <font color=\"red\">misses by $0.08M</font>.</li><li>Shares <font color=\"green\">+6.67%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17454300-cesca-therapeutics-announces-fiscal-2018-year-end-financial-results-provides-corporate-update\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3445493\" data-linked=\"Cesca Therapeutics misses on revenue\" data-tweet=\"$KOOL $THMO - Cesca Therapeutics misses on revenue https://seekingalpha.com/news/3445493-cesca-therapeutics-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3445493-cesca-therapeutics-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445492\" data-ts=\"1553544474\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYOK\" target=\"_blank\">MYOK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445492-myokardia-launches-200m-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MyoKardia launches $200M equity offering</a></h4><ul><li>MyoKardia (NASDAQ:<a href='https://seekingalpha.com/symbol/MYOK' title='MyoKardia, Inc.'>MYOK</a>) <a href=\"https://seekingalpha.com/pr/17454274-myokardia-announces-proposed-public-offering-common-stock\" target=\"_blank\">commences </a>a $200M public offering of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445492\" data-linked=\"MyoKardia launches $200M equity offering\" data-tweet=\"$MYOK - MyoKardia launches $200M equity offering https://seekingalpha.com/news/3445492-myokardia-launches-200m-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3445492-myokardia-launches-200m-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445490\" data-ts=\"1553544397\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZOM\" target=\"_blank\">ZOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445490-zomedica-readies-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zomedica readies stock offering</a></h4><ul><li>Zomedica (NYSEMKT:<a href='https://seekingalpha.com/symbol/ZOM' title='Zomedica Pharmaceuticals Corp.'>ZOM</a>) <a href=\"https://seekingalpha.com/pr/17454279-zomedica-pharmaceuticals-corp-announces-proposed-public-offering-common-shares\" target=\"_blank\">commences </a>a public offering of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445490\" data-linked=\"Zomedica readies stock offering\" data-tweet=\"$ZOM - Zomedica readies stock offering https://seekingalpha.com/news/3445490-zomedica-readies-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3445490-zomedica-readies-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445484\" data-ts=\"1553543941\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGNA\" target=\"_blank\">TGNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445484-tegnaplus-2_5-after-evercore-upgrades-to-outperform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tegna +2.5% after Evercore upgrades to Outperform</a></h4><ul>   <li>Shares in Tegna (NYSE:<a href='https://seekingalpha.com/symbol/TGNA' title='TEGNA Inc.'>TGNA</a>) were slow premarket, but have built a <font color=\"green\">2.5% gain</font> after an upgrade to Outperform at Evercore ISI.</li>    <li>The firm set a price target of $18, now implying 28% upside from current pricing of $14.10.</li>    <li>The stock is <font color=\"green\">up 26.6%</font> YTD, mostly owing to a leg up from <a href=\"https://seekingalpha.com/news/3439155-tegna-plus-13_4-percent-hitting-record-revenues-ebitda\" target=\"_blank\">strong earnings</a> at the beginning of March.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3445484\" data-linked=\"Tegna +2.5% after Evercore upgrades to Outperform\" data-tweet=\"$TGNA - Tegna +2.5% after Evercore upgrades to Outperform https://seekingalpha.com/news/3445484-tegnaplus-2_5-after-evercore-upgrades-to-outperform?source=tweet\" data-url=\"https://seekingalpha.com/news/3445484-tegnaplus-2_5-after-evercore-upgrades-to-outperform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445485\" data-ts=\"1553543907\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GORO\" target=\"_blank\">GORO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445485-gold-resource-started-buy-rating-wainwright\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gold Resource started with Buy rating at Wainwright</a></h4><ul><li>Gold Resource (<a href='https://seekingalpha.com/symbol/GORO' title='Gold Resource Corporation'>GORO</a> <font color='green'>+5.4%</font>) goes higher after H.C. Wainwright initiates coverage with a <a href=\"https://www.streetinsider.com/New+Coverage/H.C.+Wainwright+Starts+Gold+Resource+Corp+%28GORO%29+at+Buy/15291811.html\" target=\"_blank\">Buy rating</a> and $7.75 price target, saying it likes the company's focus on low-cost cash flow generating projects.</li><li>Wainwright says GORO provides investors a balance of precious and base metal production in geographically favorable jurisdictions, with additional near-term gold production.</li><li>GORO acquired the Nevada Mining Unit in 2016, which contains the Isabella Pearl Mine that is expected to commence commercial production in June 2019, but Wainwright says given the strong progress seen from its site visit earlier this month, Isabella Pearl could start producing even sooner.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445485\" data-linked=\"Gold Resource started with Buy rating at Wainwright\" data-tweet=\"$GORO - Gold Resource started with Buy rating at Wainwright https://seekingalpha.com/news/3445485-gold-resource-started-buy-rating-wainwright?source=tweet\" data-url=\"https://seekingalpha.com/news/3445485-gold-resource-started-buy-rating-wainwright\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445467\" data-ts=\"1553541768\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TDOC\" target=\"_blank\">TDOC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445467-teladoc-down-5-on-critical-forbes-article\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teladoc down 5% on critical Forbes article</a></h4><ul><li>Teladoc Health (<a href='https://seekingalpha.com/symbol/TDOC' title='Teladoc Health, Inc.'>TDOC</a> <font color=\"red\">-5.3%</font>) is down on more than 60% higher volume on the heels of an <a href=\"https://www.forbes.com/sites/greatspeculations/2019/03/25/danger-zone-incentivizing-executives-with-adjusted-ebitda/#1c672bfd4c68\" target=\"_blank\">article </a>from Forbes Contributor David Trainer who questions the company's use of non-GAAP EBITDA as its main metric of business health and its significant role in management bonuses.</li><li>The company has reported impressive increases in non-GAAP EBITDA, from -$47M in 2015 to +$13M last year, while economic earnings have plummeted from -$72M to -$186M over the same time frame.</li><li>The adjusted metric allows management to ignore the real costs of conducting business, including stock-based compensation ($44M in 2018), interest expense ($26M in 2018) and acquisition and integration costs ($10M in 2018). Mr. Trainer calls these \"adjustments\" alarming since the company relies heavily on leverage and acquisitions to grow revenue.</li><li>In its most recent proxy statement, management's cash bonuses were tied to non-GAAP EBITDA for the year (20%), non-GAAP EBITDA in Q4 (10%) and annual revenue (50%). The plan incentivizes revenue growth but allows management to exclude the costs of top line growth.</li><li>Predictably, he is bearish on the stock, seeing a potential 82% downside.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445467\" data-linked=\"Teladoc down 5% on critical Forbes article\" data-tweet=\"$TDOC - Teladoc down 5% on critical Forbes article https://seekingalpha.com/news/3445467-teladoc-down-5-on-critical-forbes-article?source=tweet\" data-url=\"https://seekingalpha.com/news/3445467-teladoc-down-5-on-critical-forbes-article\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445464\" data-ts=\"1553541131\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ITHUF\" target=\"_blank\">ITHUF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445464-ianthus-to-redeem-mpx-convertible-debt\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">iAnthus to redeem MPX convertible debt</a></h4><ul><li>iAnthus Capital (<a href='https://seekingalpha.com/symbol/ITHUF' title='iAnthus Capital Holdings, Inc.'>OTCQX:ITHUF</a>) <font color=\"red\">sinks 3.8%</font> after issuing a <a href=\"https://seekingalpha.com/pr/17453343-ianthus-capital-holdings-inc-announces-notice-redemption-debentures\" target=\"_blank\">notice of redemption </a>to the holders of ~$32.3M outstanding convertible debentures of MPX Luxembourg SARL, a wholly owned subsidiary of iAnthus.</li><li>The debentures' redemption date will be April 24, 2019; redemption price will be US$860.43 per US$1,000 principal amount.</li><li>Before redemption each holder will have the right to convert accrued principal amount of their debentures into iAnthus units. Holders electing to convert will receive 1,729.80 units (representing 289 iAnthus shares and 144.5 iAnthus warrants) for each $1,000 of accrued principal amount.</li><li>iAnthus believes most the debenture holders will elect to convert their debentures before April 23, 2019.</li><li>The convertible debentures were a legacy obligation iAnthus inherited as part of the acquisition of MPX Bioceutical.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398971-ianthus-buying-mpx-bioceutical-cannabis-wrap\" target=\"_blank\">iAnthus buying MPX Bioceutical - Cannabis wrap</a> (Oct. 19, 2018)</li></ul><div class=\"tiny-share-widget\" data-id=\"3445464\" data-linked=\"iAnthus to redeem MPX convertible debt\" data-tweet=\"$ITHUF - iAnthus to redeem MPX convertible debt https://seekingalpha.com/news/3445464-ianthus-to-redeem-mpx-convertible-debt?source=tweet\" data-url=\"https://seekingalpha.com/news/3445464-ianthus-to-redeem-mpx-convertible-debt\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445461\" data-ts=\"1553540356\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EQH\" target=\"_blank\">EQH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445461-axa-equitables-biggest-shareholder-cuts-stake-to-48_3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AXA Equitable&#39;s biggest shareholder cuts stake to 48.3%</a></h4><ul><li>AXA Equitable Holdings (<a href='https://seekingalpha.com/symbol/EQH' title='AXA Equitable Holdings, Inc.'>EQH</a> <font color='red'>-1.1%</font>) <a href=\"https://seekingalpha.com/pr/17454195-axa-equitable-holdings-inc-announces-closing-secondary-common-stock-offering-axa-s\" target=\"_blank\">completes </a>a secondary offering of 40M shares held by ASA SA (<a href='https://seekingalpha.com/symbol/AXAHF' title='AXA SA'>OTCQX:AXAHF</a>) (<a href='https://seekingalpha.com/symbol/AXAHY' title='AXA SA'>OTCQX:AXAHY</a>) at a price of $20.50 each.</li><li>Company bought back 30M shares at the same per-share price from AXA.</li><li>Greenshoe option for an additional 6M shares exercised.</li><li>AXA's ownership drops to 48.3% from 60.1%.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3444671-axa-equitable-holdings-prices-secondary-offering-40m-shares-parent\" target=\"_blank\">AXA Equitable Holdings prices secondary offering of 40M shares by parent</a> (March 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3445461\" data-linked=\"AXA Equitable&#39;s biggest shareholder cuts stake to 48.3%\" data-tweet=\"$EQH $AXAHF $AXAHY - AXA Equitable&#39;s biggest shareholder cuts stake to 48.3% https://seekingalpha.com/news/3445461-axa-equitables-biggest-shareholder-cuts-stake-to-48_3?source=tweet\" data-url=\"https://seekingalpha.com/news/3445461-axa-equitables-biggest-shareholder-cuts-stake-to-48_3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445460\" data-ts=\"1553540134\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445460-spark-networks-leads-tech-gainers-phunware-and-eltek-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spark Networks leads tech gainers; Phunware and Eltek among losers</a></h4><ul><li><b>Gainers:</b> Spark Networks (NYSEMKT:<a href='https://seekingalpha.com/symbol/LOV' title='Spark Networks SE'>LOV</a>) <font color=\"green\">+11%</font>. Intellicheck (NYSEMKT:<a href='https://seekingalpha.com/symbol/IDN' title='Intellicheck, Inc.'>IDN</a>) <font color=\"green\">+6%</font>. Qutoutiao (NASDAQ:<a href='https://seekingalpha.com/symbol/QTT' title='Qutoutiao Inc.'>QTT</a>) <font color=\"green\">+6%</font>. ACM Research (NASDAQ:<a href='https://seekingalpha.com/symbol/ACMR' title='ACM Research, Inc.'>ACMR</a>) <font color=\"green\">+6%</font>. UP Fintech Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/TIGR' title='UP Fintech Holding Limited'>TIGR</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers:</b> The9 (NASDAQ:<a href='https://seekingalpha.com/symbol/NCTY' title='The9 Limited'>NCTY</a>) <font color=\"red\">-18%</font>. Phunware (NASDAQ:<a href='https://seekingalpha.com/symbol/PHUN' title='Phunware Inc.'>PHUN</a>) <font color=\"red\">-18%</font>. Gridsum Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/GSUM' title='Gridsum Holding Inc.'>GSUM</a>) <font color=\"red\">-16%</font>. Eltek (NASDAQ:<a href='https://seekingalpha.com/symbol/ELTK' title='Eltek Ltd.'>ELTK</a>) <font color=\"red\">-15%</font>. Foresight Autonomous Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/FRSX' title='Foresight Autonomous Holdings Ltd.'>FRSX</a>) <font color=\"red\">-15%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445460\" data-linked=\"Spark Networks leads tech gainers; Phunware and Eltek among losers\" data-tweet=\"$LOV $IDN $QTT - Spark Networks leads tech gainers; Phunware and Eltek among losers https://seekingalpha.com/news/3445460-spark-networks-leads-tech-gainers-phunware-and-eltek-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3445460-spark-networks-leads-tech-gainers-phunware-and-eltek-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445456\" data-ts=\"1553538563\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRUE\" target=\"_blank\">TRUE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445456-truecar-downgraded-benchmark-take-time-to-regain-credibility\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TrueCar downgraded at Benchmark; could take time to regain credibility</a></h4><ul><li>TrueCar (<a href='https://seekingalpha.com/symbol/TRUE' title='TrueCar, Inc.'>TRUE</a> <font color='red'>-2.5%</font>) is lower after the Benchmark Company <a href=\"https://thefly.com/thestreet/realmoney/index.php/TRUEid2883550/TRUE-TrueCar-downgraded-to-Hold-on-management-credibility-issues-at-Benchmark\" target=\"_blank\">downgrades</a> shares to Hold from Buy with an $11 price target, saying it may take several quarters for TRUE management to regain credibility as each quarter is heavily scrutinized along the way.</li><li>Benchmark analyst Daniel Kurnos says his downgrade is \"not a call on any expected further near-term deterioration in operating trends,\" although he is not anticipating \"some miraculous turnaround either.\"</li><li>Kurnos also says interim CFO John Pierantoni's resignation is not a reflection on the quarter but acknowledges that TRUE's inability to find a permanent replacement within 12 months hardly conveys the best message.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445456\" data-linked=\"TrueCar downgraded at Benchmark; could take time to regain credibility\" data-tweet=\"$TRUE - TrueCar downgraded at Benchmark; could take time to regain credibility https://seekingalpha.com/news/3445456-truecar-downgraded-benchmark-take-time-to-regain-credibility?source=tweet\" data-url=\"https://seekingalpha.com/news/3445456-truecar-downgraded-benchmark-take-time-to-regain-credibility\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445453\" data-ts=\"1553537877\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLT\" target=\"_blank\">TLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445453-yields-continue-slide-stocks-give-way\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yields continue slide as stocks give way</a></h4><ul><li>The averages earlier were trying to carve out at least a modest rally, but that's quickly reversed a couple of hours before the close. The S&amp;P 500 is now <font color=\"red\">off 0.45%</font> and the Nasdaq <font color=\"red\">0.6%</font>. Helping the decline is a <font color=\"red\">1.85% drop</font> in Apple <a href=\"https://seekingalpha.com/news/3445445-apple-launches-news-card-arcade-live-updates\" target=\"_blank\">as it announces a</a> number of new products to try and fill the gap left by sluggish iPhone sales growth.</li><li>The fall in stocks is giving a boost to bond bulls, taking the 10-year Treasury yield down another six basis points to 2.385%. <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a> <font color=\"green\">+0.75%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a> <font color=\"red\">-1.5%</font>. That's the lowest yield since late 2017, and right in line with the current Fed Funds rate.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445453\" data-linked=\"Yields continue slide as stocks give way\" data-tweet=\"$TLT $TBT - Yields continue slide as stocks give way https://seekingalpha.com/news/3445453-yields-continue-slide-stocks-give-way?source=tweet\" data-url=\"https://seekingalpha.com/news/3445453-yields-continue-slide-stocks-give-way\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445450\" data-ts=\"1553536777\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445450-gold-resource-and-eldorado-gold-among-energy-materials-gainers-key-energy-services-and\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gold Resource and Eldorado Gold among Energy/Materials gainers; Key Energy Services and Ferrellgas Partners among losers</a></h4><ul><li><b>Gainers: </b>Gold Resource (NYSEMKT:<a href='https://seekingalpha.com/symbol/GORO' title='Gold Resource Corporation'>GORO</a>) <font color=\"green\">+8%</font>. Eldorado Gold (NYSE:<a href='https://seekingalpha.com/symbol/EGO' title='Eldorado Gold Corporation'>EGO</a>) <font color=\"green\">+6%</font>. Chaparral Energy (NYSE:<a href='https://seekingalpha.com/symbol/CHAP' title='Chaparral Energy, Inc.'>CHAP</a>) <font color=\"green\">+6%</font>. Golden Star Resources (NYSEMKT:<a href='https://seekingalpha.com/symbol/GSS' title='Golden Star Resources Ltd.'>GSS</a>) <font color=\"green\">+6%</font>. Sanchez Midstream Partners (NYSEMKT:<a href='https://seekingalpha.com/symbol/SNMP' title='Sanchez Midstream Partners LP'>SNMP</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Key Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/KEG' title='Key Energy Services, Inc.'>KEG</a>) <font color=\"red\">-15%</font>. Ferrellgas Partners (NYSE:<a href='https://seekingalpha.com/symbol/FGP' title='Ferrellgas Partners, L.P.'>FGP</a>) <font color=\"red\">-11%</font>. ION Geophysical (NYSE:<a href='https://seekingalpha.com/symbol/IO' title='ION Geophysical Corporation'>IO</a>) <font color=\"red\">-7%</font>. Covia (NYSE:<a href='https://seekingalpha.com/symbol/CVIA' title='Covia Holdings Corporation'>CVIA</a>) <font color=\"red\">-7%</font>. Penn Virginia (NASDAQ:<a href='https://seekingalpha.com/symbol/PVAC' title='Penn Virginia Corporation'>PVAC</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445450\" data-linked=\"Gold Resource and Eldorado Gold among Energy/Materials gainers; Key Energy Services and Ferrellgas Partners among losers\" data-tweet=\"$GORO $EGO $CHAP - Gold Resource and Eldorado Gold among Energy/Materials gainers; Key Energy Services and Ferrellgas Partners among losers https://seekingalpha.com/news/3445450-gold-resource-and-eldorado-gold-among-energy-materials-gainers-key-energy-services-and?source=tweet\" data-url=\"https://seekingalpha.com/news/3445450-gold-resource-and-eldorado-gold-among-energy-materials-gainers-key-energy-services-and\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445449\" data-ts=\"1553536555\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445449-videogame-stocks-see-volume-apple-announces-arcade-gaming-service\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Videogame stocks see volume as Apple announces Arcade gaming service</a></h4><ul>   <li>Gaming stocks are taking some small dips, unsurprisingly, as Apple teases a new entree into the game space, Apple Arcade, at its <a href=\"https://seekingalpha.com/news/3445445-apple-launches-news-live-updates\" target=\"_blank\">big media event</a>.</li>    <li>Among the big software publishers, <a href='https://seekingalpha.com/symbol/EA' title='Electronic Arts Inc.'>EA</a> is <font color=\"red\">down 1.1%</font>, Take-Two (NASDAQ:<a href='https://seekingalpha.com/symbol/TTWO' title='Take-Two Interactive Software, Inc.'>TTWO</a>) <font color=\"red\">down 0.7%</font>, Activision (NASDAQ:<a href='https://seekingalpha.com/symbol/ATVI' title='Activision Blizzard, Inc.'>ATVI</a>) <font color=\"red\">down 0.5%</font>. GameStop (NYSE:<a href='https://seekingalpha.com/symbol/GME' title='GameStop Corp.'>GME</a>) -- likely to be affected by another major digital avenue for game delivery -- isn't moving much on the announcement but is still <font color=\"red\">down 2.7%</font> on the day.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3445449\" data-linked=\"Videogame stocks see volume as Apple announces Arcade gaming service\" data-tweet=\"$EA $TTWO $ATVI - Videogame stocks see volume as Apple announces Arcade gaming service https://seekingalpha.com/news/3445449-videogame-stocks-see-volume-apple-announces-arcade-gaming-service?source=tweet\" data-url=\"https://seekingalpha.com/news/3445449-videogame-stocks-see-volume-apple-announces-arcade-gaming-service\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445448\" data-ts=\"1553536293\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/V\" target=\"_blank\">V</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445448-credit-card-players-mull-apples-entry-business\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Credit card players mull Apple&#39;s entry into business</a></h4><ul><li>None are down a lot, but Visa (<a href='https://seekingalpha.com/symbol/V' title='Visa Inc.'>V</a> <font color='red'>-0.3%</font>), Mastercard (<a href='https://seekingalpha.com/symbol/MA' title='Mastercard Incorporated'>MA</a> <font color='red'>-0.3%</font>), and AmEx (<a href='https://seekingalpha.com/symbol/AXP' title='American Express Company'>AXP</a> <font color='red'>-0.9%</font>) have all given up some ground after the <a href=\"https://seekingalpha.com/news/3445445-apple-launches-news-credit-card-live-updates\" target=\"_blank\">announcement of the</a> Apple Card.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445448\" data-linked=\"Credit card players mull Apple&#39;s entry into business\" data-tweet=\"$V $MA $AXP - Credit card players mull Apple&#39;s entry into business https://seekingalpha.com/news/3445448-credit-card-players-mull-apples-entry-business?source=tweet\" data-url=\"https://seekingalpha.com/news/3445448-credit-card-players-mull-apples-entry-business\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>52&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445445\" data-ts=\"1553534317\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445445-apple-launches-news-channels-tv-and\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple launches News+, Channels, TV+ and more</a></h4><ul><li><strong>Apple TV+ original content</strong>: <a href=\"https://seekingalpha.com/news/3300239-wsj-apple-signs-deal-spielberg-nbc-bring-back-amazing-stories\" target=\"_blank\">Steven Spielberg</a>, <a href=\"https://seekingalpha.com/news/3310291-apples-first-scripted-tv-show\" target=\"_blank\">Reese Witherspoon and Jennifer Aniston,</a> and <a href=\"https://variety.com/2018/tv/news/jason-momoa-apple-see-1202869906/\" target=\"_blank\">Jason Momoa</a> and Alfre Woodard all come out to announce their previously announced projects. Sesame Street also came out to talk about its coding-based children's program. Note that these were all talks with stills and not video clip promos. Update: The clips came later, in a montage.</li><li>Apple TV+ is coming this fall.</li><li><strong>Apple TV Channels</strong>: A section within the redesigned TV app includes network TV from satellite and cable, premium channels including HBO and Showtime, sports add-ons, and the ability to rent and watch movies. Update: Users can subscribe to premium channels straight through the app.</li><li>The special Kids section is a \"safe place to explore together\" with its content curated by humans.</li><li>The redesign will arrive through a software update in May to the usual supported devices. The app will launch in Samsung smart TVs this spring and come to Roku and Amazon streaming devices.</li><li><strong>Apple Arcade:</strong> Collection of brand new games from a variety of studios with Apple backing the development.</li><li>Arcade will exist in the App store. Subscribers can download included games and enjoy unlimited play across Apple mobile and TV devices and all games are available to play offline.</li><li>Arcade will start with over 100 games with more to come.</li><li>Apple Arcade will launch this fall and pricing and more details will come later.</li><li><strong>Apple Card:</strong> Apple Pay launches the Apple Card credit card. Users can sign up through an iPhone, get an approval, and start using the card immediately.</li><li>The Card gets stored in the Wallet app, which gets some new features to show the typical credit card data like minimum payment due and transaction history. Users can also track spending habits for budgeting purposes.</li><li>Apple Card has daily cash, which is the 2% cashback reward that pays out every day the Card is used. Direct purchases from or through Apple carry a 3% cashback rate. Update: And if you get the physical card, there's a 1% cashback rate.</li><li>The Card has no late, annual, penalty or any other type of fee. And it's partnered with Goldman Sachs (NYSE:<a href='https://seekingalpha.com/symbol/GS' title='The Goldman Sachs Group, Inc.'>GS</a>) and Mastercard (NYSE:<a href='https://seekingalpha.com/symbol/MA' title='Mastercard Incorporated'>MA</a>).</li><li><strong>Original post:</strong> Apple's (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) \"Show Time\" event kicks off with magazine subscriptions available in the new service Apple News+, which exists as a tab in the News app.</li><li>The 300 magazines offered include Time, Vogue, Popular Science, Sports Illustrated, and Fortune. Apple says News+ is the only place to find all of these titles in one service.</li><li>News+ also includes subscriptions to The Wall Street Journal, Los Angeles Times, and premium digital sites like The Skimm and TechCrunch.</li><li>Cost: $9.99 per month and Family Sharing is available for free. The service is available today with a one-month free trial in the U.S. and Canada.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445445\" data-linked=\"Apple launches News+, Channels, TV+ and more\" data-tweet=\"$AAPL $GS $MA - Apple launches News+, Channels, TV+ and more https://seekingalpha.com/news/3445445-apple-launches-news-channels-tv-and?source=tweet\" data-url=\"https://seekingalpha.com/news/3445445-apple-launches-news-channels-tv-and\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>205&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445444\" data-ts=\"1553534297\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445444-avenatti-arrested-for-extortion-scheme-against-nike\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Avenatti arrested for extortion scheme against Nike</a></h4><ul><li>Less than an hour after Michael Avenatti announced an upcoming press conference to detail a major basketball-related scheme by Nike (NYSE:<a href='https://seekingalpha.com/symbol/NKE' title='NIKE, Inc.'>NKE</a>), the attorney <a href=\"https://www.cnbc.com/2019/03/25/michael-avenatti-to-be-charged-with-wire-and-bank-fraud.html\" target=\"_blank\">has been arrested</a> - charged with a $20M extortion attempt against the company.</li><li>Shares remain <font color=\"red\">down 0.3%</font> for the day.</li><li><a href=\"https://www.documentcloud.org/documents/5780145-U-S-v-Michael-Avenatti-Complaint.html\" target=\"_blank\">Full complaint here</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3445437-nike-avenatti-target-shares-dip\" target=\"_blank\">Nike an Avenatti target; shares dip</a> (March 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3445444\" data-linked=\"Avenatti arrested for extortion scheme against Nike\" data-tweet=\"$NKE - Avenatti arrested for extortion scheme against Nike https://seekingalpha.com/news/3445444-avenatti-arrested-for-extortion-scheme-against-nike?source=tweet\" data-url=\"https://seekingalpha.com/news/3445444-avenatti-arrested-for-extortion-scheme-against-nike\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>53&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445440\" data-ts=\"1553533248\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445440-yirendai-leads-financial-gainers-cousins-properties-and-medley-management-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yirendai leads financial gainers; Cousins Properties and Medley Management among losers</a></h4><ul><li><b>Gainers:</b> Yirendai (NYSE:<a href='https://seekingalpha.com/symbol/YRD' title='Yirendai Ltd.'>YRD</a>) <font color=\"green\">+8%</font>. TIER REIT (NYSE:<a href='https://seekingalpha.com/symbol/TIER' title='TIER REIT, Inc.'>TIER</a>) <font color=\"green\">+7%</font>. Medallion Financial (NASDAQ:<a href='https://seekingalpha.com/symbol/MFIN' title='Medallion Financial'>MFIN</a>) <font color=\"green\">+6%</font>. China Bat Group (NASDAQ:<a href='https://seekingalpha.com/symbol/GLG' title='China Bat Group, Inc.'>GLG</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers:</b> Altisource Asset Management (NYSEMKT:<a href='https://seekingalpha.com/symbol/AAMC' title='Altisource Asset Management Corporation'>AAMC</a>) <font color=\"red\">-16%</font>. Cousins Properties (NYSE:<a href='https://seekingalpha.com/symbol/CUZ' title='Cousins Properties Incorporated'>CUZ</a>) <font color=\"red\">-6%</font>. Medley Management (NYSE:<a href='https://seekingalpha.com/symbol/MDLY' title='Medley Management Inc.'>MDLY</a>) <font color=\"red\">-6%</font>. China Internet Nationwide Financial Services (NASDAQ:<a href='https://seekingalpha.com/symbol/CIFS' title='China Internet Nationwide Financial Services Inc.'>CIFS</a>) <font color=\"red\">-5%</font>. Spirit MTA (NYSE:<a href='https://seekingalpha.com/symbol/SMTA' title='Spirit MTA REIT'>SMTA</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445440\" data-linked=\"Yirendai leads financial gainers; Cousins Properties and Medley Management among losers\" data-tweet=\"$YRD $TIER $MFIN - Yirendai leads financial gainers; Cousins Properties and Medley Management among losers https://seekingalpha.com/news/3445440-yirendai-leads-financial-gainers-cousins-properties-and-medley-management-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3445440-yirendai-leads-financial-gainers-cousins-properties-and-medley-management-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445438\" data-ts=\"1553532595\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MEOH\" target=\"_blank\">MEOH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445438-airbus-said-to-win-long-awaited-china-aircraft-order\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Airbus said to win long-awaited China aircraft order</a></h4><ul><li>Boeing (<a href='https://seekingalpha.com/symbol/BA' title='The Boeing Company'>BA</a> <font color=\"green\">+0.9%</font>) slips from highs of the day after a Bloomberg report that Airbus (<a href='https://seekingalpha.com/symbol/EADSF' title='Airbus SE'>OTCPK:EADSF</a>, <a href='https://seekingalpha.com/symbol/EADSY' title='Airbus SE'>OTCPK:EADSY</a>) has <a href=\"https://finance.yahoo.com/news/airbus-seals-long-awaited-aircraft-163320433.html\" target=\"_blank\">sealed a long-awaited aircraft order from China</a>.</li><li>The $35B order consists of 290 A320-series narrow-body planes and 10 A350 wide-bodies; the latest A320neo model has a list price of $110.6M and the A350-900 lists for $317.4M before discounts.</li><li>Boeing shares are higher after Ethiopian Airlines says it <a href=\"https://seekingalpha.com/news/3445290-ethiopian-airlines-believes-boeing\" target=\"_blank\">still believes in the company</a> after the recent 737 MAX 8 crash and Qatar Airways <a href=\"https://www.reuters.com/article/us-ethiopia-airplane-qatar-airways/qatar-airways-backs-boeing-despite-max-crash-crisis-idUSKCN1R610L\" target=\"_blank\">offers its support</a>, expressing \"full confidence in Boeing and their ability to resolve any technical issue.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3445438\" data-linked=\"Airbus said to win long-awaited China aircraft order\" data-tweet=\"$MEOH $BA $EADSF - Airbus said to win long-awaited China aircraft order https://seekingalpha.com/news/3445438-airbus-said-to-win-long-awaited-china-aircraft-order?source=tweet\" data-url=\"https://seekingalpha.com/news/3445438-airbus-said-to-win-long-awaited-china-aircraft-order\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>59&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445436\" data-ts=\"1553532167\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445436-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul><li><strong>Gainers: </strong>Hunter Maritime Acquisition (NASDAQ:<a href='https://seekingalpha.com/symbol/HUNT' title='Hunter Maritime Acquisition Corp.'>HUNT</a>) <font color=\"green\">+50%</font>. NantKwest (NASDAQ:<a href='https://seekingalpha.com/symbol/NK' title='NantKwest, Inc.'>NK</a>) <font color=\"green\">+40%</font>. Avaya Holdings (NYSE:<a href='https://seekingalpha.com/symbol/AVYA' title='Avaya Holdings Corp.'>AVYA</a>) <font color=\"green\">+36%</font>.  Curis (NASDAQ:<a href='https://seekingalpha.com/symbol/CRIS' title='Curis, Inc.'>CRIS</a>) <font color=\"green\">+31%</font>. Catalyst Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CPRX' title='Catalyst Pharmaceuticals, Inc.'>CPRX</a>) <font color=\"green\">+20%</font>. Axsome Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics, Inc.'>AXSM</a>) <font color=\"green\">+17%</font>. Urban Tea (NASDAQ:<a href='https://seekingalpha.com/symbol/MYT' title='Urban Tea, Inc.'>MYT</a>) <font color=\"green\">+16%</font>.  Spark Networks (NYSEMKT:<a href='https://seekingalpha.com/symbol/LOV' title='Spark Networks SE'>LOV</a>) <font color=\"green\">+14%</font>. Iterum Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ITRM' title='Iterum Therapeutics plc'>ITRM</a>) <font color=\"green\">+13%</font>. Citius Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CTXR' title='Citius Pharmaceuticals, Inc.'>CTXR</a>) <font color=\"green\">+13%</font>.</li><li><strong>Losers: </strong>Proteostasis Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics, Inc.'>PTI</a>) <font color=\"red\">-61%</font>. Recro Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/REPH' title='Recro Pharma, Inc.'>REPH</a>) <font color=\"red\">-35%</font>. CCA Industries (NYSEMKT:<a href='https://seekingalpha.com/symbol/CAW' title='CCA Industries, Inc.'>CAW</a>) <font color=\"red\">-18%</font>. Phunware (NASDAQ:<a href='https://seekingalpha.com/symbol/PHUN' title='Phunware Inc.'>PHUN</a>) <font color=\"red\">-16%</font>. Altisource Asset Management (NYSEMKT:<a href='https://seekingalpha.com/symbol/AAMC' title='Altisource Asset Management Corporation'>AAMC</a>) <font color=\"red\">-16%</font>. Sorrento Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a>) <font color=\"red\">-16%</font>. Motif Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/MTFB' title='Motif Bio plc'>MTFB</a>) <font color=\"red\">-15%</font>. The9 (NASDAQ:<a href='https://seekingalpha.com/symbol/NCTY' title='The9 Limited'>NCTY</a>) <font color=\"red\">-15%</font>. Aqua Metals (NASDAQ:<a href='https://seekingalpha.com/symbol/AQMS' title='Aqua Metals, Inc.'>AQMS</a>) <font color=\"red\">-15%</font>. Gridsum Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/GSUM' title='Gridsum Holding Inc.'>GSUM</a>) <font color=\"red\">-13%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445436\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$HUNT $NK $AVYA - Midday Gainers / Losers https://seekingalpha.com/news/3445436-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3445436-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:42 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445437\" data-ts=\"1553532125\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445437-nike-avenatti-target-shares-dip\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nike an Avenatti target; shares dip</a></h4><ul><li>Michael Avenatti (yes, that guy) <a href=\"https://twitter.com/MichaelAvenatti/status/1110213957170749440\" target=\"_blank\">promises a press conference</a> tomorrow morning to \"disclose a major high school/college basketball scandal perpetrated by Nike (NYSE:<a href='https://seekingalpha.com/symbol/NKE' title='NIKE, Inc.'>NKE</a>).\"</li><li>Avenatti: \"This criminal conduct reaches the highest levels of Nike and involves some of the biggest names in college basketball.\"</li><li>NKE has moved from modestly in the green to a<font color=\"red\"> 0.2% loss</font> for the day.</li><li><strong>Updated at 1:20 ET:</strong> Avenatti <a href=\"https://seekingalpha.com/news/3445444-avenatti-arrested-extortion-scheme-nike\" target=\"_blank\">has been arrested</a> and charged with a $20M extortion attempt against Nike.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445437\" data-linked=\"Nike an Avenatti target; shares dip\" data-tweet=\"$NKE - Nike an Avenatti target; shares dip https://seekingalpha.com/news/3445437-nike-avenatti-target-shares-dip?source=tweet\" data-url=\"https://seekingalpha.com/news/3445437-nike-avenatti-target-shares-dip\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445434\" data-ts=\"1553531896\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROKU\" target=\"_blank\">ROKU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445434-rokuplus-4_4-ceo-standing-apple-event\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roku +4.4% with CEO standing by at Apple event</a></h4><ul>   <li>Roku (NASDAQ:<a href='https://seekingalpha.com/symbol/ROKU' title='Roku, Inc.'>ROKU</a>) is <font color=\"green\">up 4.4%</font> ahead of Apple's big streaming-TV announcements, amid notes that <a href=\"https://twitter.com/pkafka/status/1110214192038961152\" target=\"_blank\">CEO Anthony Wood</a> is in the Apple staging area.</li>    <li>The company was absent from the names announcing a deal with Apple at CES, Peter Kafka notes, but they look to be part of the news today.</li>    <li>Observers are watching to see if AirPlay 2 support will be enabled on Roku devices.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3445434\" data-linked=\"Roku +4.4% with CEO standing by at Apple event\" data-tweet=\"$ROKU - Roku +4.4% with CEO standing by at Apple event https://seekingalpha.com/news/3445434-rokuplus-4_4-ceo-standing-apple-event?source=tweet\" data-url=\"https://seekingalpha.com/news/3445434-rokuplus-4_4-ceo-standing-apple-event\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445429\" data-ts=\"1553531388\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLAN\" target=\"_blank\">PLAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445429-anaplanplus-4-on-buy-start-upside-potential\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Anaplan +4% on Buy start, upside potential</a></h4><ul><li>Monness Crespi Hardt initiates Anaplan (NYSE:<a href='https://seekingalpha.com/symbol/PLAN' title='Anaplan, Inc.'>PLAN</a>) at Buy with a Street-high PT of $50 citing the \"large potential market opportunity\" around cloud-based planning solutions.</li><li>Analyst Brian White also notes PLAN's \"strong growth, subscription model, unique value proposition\" and its potential to be acquired, which all justify a premium valuation.</li><li>White expects 30% sales growth in 2019 and 29% growth in 2020 with upside potential.</li><li>Anaplan shares are<font color=\"green\"> up 4.2%</font> to $40.60.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445429\" data-linked=\"Anaplan +4% on Buy start, upside potential\" data-tweet=\"$PLAN - Anaplan +4% on Buy start, upside potential https://seekingalpha.com/news/3445429-anaplanplus-4-on-buy-start-upside-potential?source=tweet\" data-url=\"https://seekingalpha.com/news/3445429-anaplanplus-4-on-buy-start-upside-potential\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445428\" data-ts=\"1553531378\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLUSF\" target=\"_blank\">GLUSF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445428-gluskin-sheff-soars-29-on-acquisition-pact-onex\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gluskin Sheff soars 29% on acquisition pact with Onex</a></h4><ul><li>Gluskin Sheff + Associates (<a href='https://seekingalpha.com/symbol/GLUSF' title='Gluskin Sheff + Associates Inc.'>OTC:GLUSF</a>), a Canadian independent wealth management firm,<font color=\"green\"> surges 29%</font> after <a href=\"https://seekingalpha.com/pr/17453124-onex-agrees-acquire-gluskin-sheff\" target=\"_blank\">agreeing</a> to be acquired by Onex (<a href='https://seekingalpha.com/symbol/ONEXF' title='Onex Corporation'>OTCPK:ONEXF</a> <font color='green'>+1.1%</font>) for C$14.25 (US$10.62) per share.</li><li>Price represents a 28% premium to Gluskin Sheff's closing price on March 22, 2019.</li><li>Total cash consideration is ~C$445M.</li><li>Expected to close in H1 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445428\" data-linked=\"Gluskin Sheff soars 29% on acquisition pact with Onex\" data-tweet=\"$GLUSF $ONEXF - Gluskin Sheff soars 29% on acquisition pact with Onex https://seekingalpha.com/news/3445428-gluskin-sheff-soars-29-on-acquisition-pact-onex?source=tweet\" data-url=\"https://seekingalpha.com/news/3445428-gluskin-sheff-soars-29-on-acquisition-pact-onex\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445425\" data-ts=\"1553530952\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WCG\" target=\"_blank\">WCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445425-managed-care-providers-lag-market-investors-pare-positions\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Managed care providers lag market as investors pare positions</a></h4><ul><li>Managed care organizations are in the red, adding to recent bearishness. Goldman Sachs' Asad Haider says the softness has more to do with investors paring positions in the overbought industry than fundamentals, adding that election and policy themes appear to be the dominant issues.</li><li>Selected tickers: WellCare Health Plans (<a href='https://seekingalpha.com/symbol/WCG' title='WellCare Health Plans, Inc.'>WCG</a> <font color=\"red\">-0.4%</font>), UnitedHealth Group (<a href='https://seekingalpha.com/symbol/UNH' title='UnitedHealth Group Incorporated'>UNH</a> <font color=\"red\">-0.5%</font>), Molina Healthcare (<a href='https://seekingalpha.com/symbol/MOH' title='Molina Healthcare, Inc.'>MOH</a> <font color=\"red\">-2%</font>), Cigna (<a href='https://seekingalpha.com/symbol/CI' title='Cigna Corporation'>CI</a> <font color=\"red\">-1.4%</font>), Centene (<a href='https://seekingalpha.com/symbol/CNC' title='Centene Corporation'>CNC</a> <font color=\"red\">-0.5%</font>), Anthem (<a href='https://seekingalpha.com/symbol/ANTM' title='Anthem, Inc.'>ANTM</a> <font color=\"red\">-1.3%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3445425\" data-linked=\"Managed care providers lag market as investors pare positions\" data-tweet=\"$WCG $UNH $MOH - Managed care providers lag market as investors pare positions https://seekingalpha.com/news/3445425-managed-care-providers-lag-market-investors-pare-positions?source=tweet\" data-url=\"https://seekingalpha.com/news/3445425-managed-care-providers-lag-market-investors-pare-positions\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445407\" data-ts=\"1553529076\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPRX\" target=\"_blank\">CPRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445407-catalyst-pharma-adds-to-rally-on-firdapse-outlook-up-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Catalyst Pharma adds to rally on Firdapse outlook, up 15%</a></h4><ul><li>Catalyst Pharmaceuticals (<a href='https://seekingalpha.com/symbol/CPRX' title='Catalyst Pharmaceuticals, Inc.'>CPRX</a> <font color=\"green\">+14.7%</font>) is up on 50% higher volume. Shares have rallied over <font color=\"green\">50%</font> since last week when it delivered a corporate overview at Oppenheimer's healthcare event.</li><li>Investors appear more confident with the prospects of Firdapse (amifampridine), approved in the U.S. in late November 2018 for a rare autoimmune disorder called Lambert-Eaton myasthenic syndrome &#40;LEMS&#41;. Commercial launch began in mid-January. There has been a bit of <a href=\"https://seekingalpha.com/news/3428974-catalyst-pharma-sen-sanders-crosshairs-firdapse-pricing-shares-4-percent-premarket\" target=\"_blank\">controversy </a>over its $375K list price since patients had previous access to it at no cost from a New Jersey drug maker, creating concerns about its market potential.</li><li>Per its <a href=\"https://seekingalpha.com/article/4250264-catalyst-pharmaceuticals-cprx-present-oppenheimer-29th-annual-healthcare-conference-slideshow\" target=\"_blank\">slide presentation</a>, there are two potential catalysts that should happen later this year: the release of topline data from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT02562066?spons=catalyst&amp;phase=12&amp;rank=7\" target=\"_blank\">Phase 3</a> clinical trial in congenital myasthenic syndromes &#40;CMS&#41; and topline data from another <a href=\"https://clinicaltrials.gov/ct2/show/NCT03304054?spons=catalyst&amp;phase=12&amp;rank=5\" target=\"_blank\">Phase 3</a> in muscle-specific tyrosine kinase myasthenia gravis (MuSK-MG).</li><li>Topline data from a proof-of-concept <a href=\"https://clinicaltrials.gov/ct2/show/NCT03781479?spons=catalyst&amp;phase=12&amp;rank=3\" target=\"_blank\">Phase 2</a> study in spinal muscular atrophy type 3 should be available in H1 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445407\" data-linked=\"Catalyst Pharma adds to rally on Firdapse outlook, up 15%\" data-tweet=\"$CPRX - Catalyst Pharma adds to rally on Firdapse outlook, up 15% https://seekingalpha.com/news/3445407-catalyst-pharma-adds-to-rally-on-firdapse-outlook-up-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3445407-catalyst-pharma-adds-to-rally-on-firdapse-outlook-up-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445411\" data-ts=\"1553528352\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445411-ad-tech-firms-drop-google-mulls-chrome-ad-changes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ad-tech firms drop as Google mulls Chrome ad changes</a></h4><ul>   <li>Ad-tech firms are lower today in the wake of a report that Google (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet Inc.'>GOOG</a> <font color=\"red\">-0.5%</font>, <a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet Inc.'>GOOGL</a> <font color=\"red\">-0.4%</font>) is looking at what could be sweeping changes to its ad tools, which could result in targeting restrictions at the browser level.</li>    <li><i>Adweek</i> reported that a complex set of deliberations across Google businesses make it likely that the company will make <a href=\"https://www.adweek.com/programmatic/google-mulls-third-party-ad-targeting-restrictions/\" target=\"_blank\">changes to its Chrome browser</a> with heavy effect on how ad-tech vendors operate within it.</li>    <li>Those changes span a range of outcomes but observers are prearing for a change as heavy as previous ones made by Apple's Safari and Mozilla's Firefox.</li>    <li>Criteo (NASDAQ:<a href='https://seekingalpha.com/symbol/CRTO' title='Criteo S.A.'>CRTO</a>) is <font color=\"red\">8.3% lower</font> today to three-month lows, while The Trade Desk (NASDAQ:<a href='https://seekingalpha.com/symbol/TTD' title='The Trade Desk, Inc.'>TTD</a>) is <font color=\"red\">off 2%</font>. Elsewhere, Rubicon Project (NYSE:<a href='https://seekingalpha.com/symbol/RUBI' title='the Rubicon Project, Inc.'>RUBI</a>) is <font color=\"green\">up 3.2%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3445411\" data-linked=\"Ad-tech firms drop as Google mulls Chrome ad changes\" data-tweet=\"$GOOG $GOOGL $CRTO - Ad-tech firms drop as Google mulls Chrome ad changes https://seekingalpha.com/news/3445411-ad-tech-firms-drop-google-mulls-chrome-ad-changes?source=tweet\" data-url=\"https://seekingalpha.com/news/3445411-ad-tech-firms-drop-google-mulls-chrome-ad-changes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445410\" data-ts=\"1553528318\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EMRAF\" target=\"_blank\">EMRAF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445410-emera-to-sell-maine-unit-to-enmax-in-c-1_8b-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Emera to sell Maine unit to Enmax in C$1.8B deal</a></h4><ul><li>Canadian utility Enmax <a href=\"https://business.financialpost.com/commodities/energy/emera-to-sell-maine-operations-in-deal-valued-at-1-8b-including-debt\" target=\"_blank\">agrees to acquire</a> Emera's (<a href='https://seekingalpha.com/symbol/EMRAF' title='Emera Incorporated'>OTCPK:EMRAF</a> <font color='green'>+2.7%</font>) Maine electric transmission and distribution unit in a deal valued at C$1.8B including debt.</li><li>The deal is subject to regulatory approvals from the Maine Public Utilities Commission  and the U.S. Federal Energy Regulatory Commission.</li><li>Emera, which earlier announced the sale of its New England Gas Generation portfolio, says the two divestitures will raise ~C$2.1B.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445410\" data-linked=\"Emera to sell Maine unit to Enmax in C$1.8B deal\" data-tweet=\"$EMRAF - Emera to sell Maine unit to Enmax in C$1.8B deal https://seekingalpha.com/news/3445410-emera-to-sell-maine-unit-to-enmax-in-c-1_8b-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3445410-emera-to-sell-maine-unit-to-enmax-in-c-1_8b-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445402\" data-ts=\"1553526616\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNP\" target=\"_blank\">SNP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445402-sinopecminus-2-quarterly-profit-lowest-since-least-q3-2016\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sinopec -2% as quarterly profit lowest since at least Q3 2016</a></h4><ul><li>Sinopec (<a href='https://seekingalpha.com/symbol/SNP' title='China Petroleum & Chemical Corporation'>SNP</a> <font color='red'>-2.3%</font>) records its <a href=\"https://www.reuters.com/article/china-sinopec-results/chinas-sinopec-reports-lowest-quarterly-profit-since-at-least-q3-2016-idUSL3N2111F6\" target=\"_blank\">smallest quarterly net profit since at least Q3 2016</a>, plunging 76% Y/Y to 3.1B yuan ($461.5M) in Q4 as oil trading unit Unipec lost 4.65B yuan on crude oil hedging.</li><li>But for the full year, SNP's net earnings climbed 23% to 63B yuan, the best annual results since 2013, and total revenues rose 22% to 2.89T yuan from 2.36T yuan a year earlier.</li><li>SNP says it <a href=\"https://www.reuters.com/article/china-sinopec-results/update-1-chinas-sinopec-lifts-upstream-capex-to-four-year-high-plans-record-crude-runs-idUSL3N21B08K\" target=\"_blank\">raised upstream capex by 41%</a> last year to 59.6B yuan ($8.9B), its highest since 2014, partially in response to the Chinese government's call for energy security.</li><li>Untapped proven crude reserve from the Shengli field - SNP's biggest - fell to 16M barrels by year-end 2018 from 49M barrels at the end of 2017.</li><li>SNP also says it plans to increase its crude processing rate to 4.92M bbl/day in 2019, up slightly from 4.88M bbl/day last year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445402\" data-linked=\"Sinopec -2% as quarterly profit lowest since at least Q3 2016\" data-tweet=\"$SNP - Sinopec -2% as quarterly profit lowest since at least Q3 2016 https://seekingalpha.com/news/3445402-sinopecminus-2-quarterly-profit-lowest-since-least-q3-2016?source=tweet\" data-url=\"https://seekingalpha.com/news/3445402-sinopecminus-2-quarterly-profit-lowest-since-least-q3-2016\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445399\" data-ts=\"1553526413\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NK\" target=\"_blank\">NK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445399-nantkwest-up-30-on-39m-soon-shiong-investment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NantKwest up 30% on $39M Soon-Shiong investment</a></h4><ul><li>Thinly traded micro cap NantKwest (<a href='https://seekingalpha.com/symbol/NK' title='NantKwest, Inc.'>NK</a> <font color=\"green\">+30.2%</font>) is up almost a 12x surge in volume following its <a href=\"https://seekingalpha.com/pr/17453531-nantkwest-chairman-and-ceo-dr-patrick-soon-shiong-exercises-39-million-warrants-options\" target=\"_blank\">announcement </a>that Chairman &amp; CEO Patrick Soon-Shiong, M.D. has invested $39.2M in the company via warrant purchases.</li><li>He exercised ~17.6M warrants at $1.9984 and ~1.9M at $2.1983.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445399\" data-linked=\"NantKwest up 30% on $39M Soon-Shiong investment\" data-tweet=\"$NK - NantKwest up 30% on $39M Soon-Shiong investment https://seekingalpha.com/news/3445399-nantkwest-up-30-on-39m-soon-shiong-investment?source=tweet\" data-url=\"https://seekingalpha.com/news/3445399-nantkwest-up-30-on-39m-soon-shiong-investment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445398\" data-ts=\"1553526076\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445398-curis-leads-healthcare-gainers-recro-pharma-and-sorrento-therapeutics-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Curis leads healthcare gainers; Recro Pharma and Sorrento Therapeutics among losers</a></h4><ul><li><b>Gainers: </b>Curis (NASDAQ:<a href='https://seekingalpha.com/symbol/CRIS' title='Curis, Inc.'>CRIS</a>) <font color=\"green\">+47%</font>. NantKwest (NASDAQ:<a href='https://seekingalpha.com/symbol/NK' title='NantKwest, Inc.'>NK</a>) <font color=\"green\">+31%</font>. Axsome Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics, Inc.'>AXSM</a>) <font color=\"green\">+17%</font>. Check-Cap (NASDAQ:<a href='https://seekingalpha.com/symbol/CHEK' title='Check-Cap Ltd.'>CHEK</a>) <font color=\"green\">+13%</font>. Catalyst Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CPRX' title='Catalyst Pharmaceuticals, Inc.'>CPRX</a>) <font color=\"green\">+11%</font>.</li><li><b>Losers: </b>Proteostasis Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics, Inc.'>PTI</a>) <font color=\"red\">-59%</font>. Recro Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/REPH' title='Recro Pharma, Inc.'>REPH</a>) <font color=\"red\">-36%</font>. Motif Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/MTFB' title='Motif Bio plc'>MTFB</a>) <font color=\"red\">-13%</font>. Bio-Path Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a>) <font color=\"red\">-13%</font>. Sorrento Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a>) <font color=\"red\">-13%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445398\" data-linked=\"Curis leads healthcare gainers; Recro Pharma and Sorrento Therapeutics among losers\" data-tweet=\"$CRIS $NK $AXSM - Curis leads healthcare gainers; Recro Pharma and Sorrento Therapeutics among losers https://seekingalpha.com/news/3445398-curis-leads-healthcare-gainers-recro-pharma-and-sorrento-therapeutics-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3445398-curis-leads-healthcare-gainers-recro-pharma-and-sorrento-therapeutics-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445393\" data-ts=\"1553525007\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NEM\" target=\"_blank\">NEM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445393-newmont-offers-special-dividend-shareholders-back-goldcorp-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Newmont offers special dividend if shareholders back Goldcorp deal</a></h4><ul><li>Newmont Mining (<a href='https://seekingalpha.com/symbol/NEM' title='Newmont Mining Corporation'>NEM</a> <font color='green'>+1.2%</font>) tries to <a href=\"https://www.wsj.com/articles/newmont-tries-to-end-revolt-over-goldcorp-deal-with-special-dividend-11553523422\" target=\"_blank\">soothe a budding shareholder revolt</a> that could have killed its takeover of Goldcorp (<a href='https://seekingalpha.com/symbol/GG' title='Goldcorp Inc.'>GG</a> <font color='green'>+2.7%</font>), promising to issue a <a href=\"https://seekingalpha.com/news/3445296-newmont-mining-declares-0_88-dividend\" target=\"_blank\">special $0.88/share dividend</a> to its investors if the merger deal is approved by both companies' shareholders next month.</li><li>NEM shareholders Paulson &amp; Co. and Van Eck International said last week (<a href=\"https://seekingalpha.com/news/3444952-paulson-says-newmont-minings-merger-deal-goldcorp\" target=\"_blank\">I</a>, <a href=\"https://seekingalpha.com/news/3445163-newmont-investor-vaneck-backs-paulsons-concerns-goldcorp-deal\" target=\"_blank\">II</a>) the merger proposal transferred to GG shareholders too much of the nearly $5B in synergies from a separate Nevada joint venture with Barrick Gold.</li><li>\u201cThe special dividend allows us to pass on the full, after tax, synergies that would have gone to the Goldcorp investors,\u201d NEM COO Tom Palmer says.</li><li>Separately, GG says proxy advisory firm ISS recommends its shareholders support NEM\u2019s takeover offer when they vote on April 4; NEM shareholders will vote on April 11.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445393\" data-linked=\"Newmont offers special dividend if shareholders back Goldcorp deal\" data-tweet=\"$NEM $GG - Newmont offers special dividend if shareholders back Goldcorp deal https://seekingalpha.com/news/3445393-newmont-offers-special-dividend-shareholders-back-goldcorp-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3445393-newmont-offers-special-dividend-shareholders-back-goldcorp-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445370\" data-ts=\"1553523227\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XERS\" target=\"_blank\">XERS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445370-xeris-up-1-on-positive-room-temp-glucagon-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xeris up 1% on positive room-temp glucagon data</a></h4><ul><li>Xeris Pharmaceuticals (<a href='https://seekingalpha.com/symbol/XERS' title='Xeris Pharmaceuticals, Inc.'>XERS</a> <font color=\"green\">+0.8%</font>) is up on light volume on the heels of <a href=\"https://seekingalpha.com/pr/17453729-xeris-pharmaceuticals-presents-new-clinical-economic-impact-data-developmental-ready-use\" target=\"_blank\">new data</a> on its ready-to-use &#40;RTU&#41; room-temperature liquid glucagon.</li><li>Results from a Phase 2 study, presented at the Endocrine Society Annual Meeting in New Orleans, in patients with congenital hyperinsulinemia who received RTU glucagon via an Omnipod infusion pump experienced \"positive clinical responses\" compared to placebo.</li><li>Data presented at the Academy of Managed Care Pharmacy\u2019s AMCP Managed Care &amp; Specialty Pharmacy Annual Meeting in San Diego showed the economic benefit of the Gvoke HypoPen (Xeris' auto-injector) for the treatment of severe hypoglycemic events. The company says the results support increased patient access.</li><li>Its U.S. marketing application is currently under FDA review with a June 10 action date.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445370\" data-linked=\"Xeris up 1% on positive room-temp glucagon data\" data-tweet=\"$XERS - Xeris up 1% on positive room-temp glucagon data https://seekingalpha.com/news/3445370-xeris-up-1-on-positive-room-temp-glucagon-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3445370-xeris-up-1-on-positive-room-temp-glucagon-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445377\" data-ts=\"1553523172\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445377-cetvplus-6_9-on-strategic-alternatives-exploration\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CETV +6.9% on strategic alternatives exploration</a></h4><ul>   <li>Central European Media (NASDAQ:<a href='https://seekingalpha.com/symbol/CETV' title='Central European Media Enterprises Ltd.'>CETV</a>) is <font color=\"green\">up 6.9%</font> to a one-month high after announcing its board has started a process to <a href=\"https://seekingalpha.com/pr/17453724-central-european-media-enterprises-announces-plan-review-strategic-alternatives\" target=\"_blank\">explore strategic alternatives</a>.</li>    <li>At the moment that could include an outright sale of all or part of the company, along with a merger with a strategic partner, a recapitalization or \"continuing to execute on CME's long-term business plan.\"</li>    <li>Top shareholder AT&amp;T (<a href=\"http://seekingalpha.com/symbol/T\" target=\"_blank\">T</a> <font color=\"red\">-0.4%</font>) supports CME's plans, the company notes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3445377\" data-linked=\"CETV +6.9% on strategic alternatives exploration\" data-tweet=\"$CETV $T - CETV +6.9% on strategic alternatives exploration https://seekingalpha.com/news/3445377-cetvplus-6_9-on-strategic-alternatives-exploration?source=tweet\" data-url=\"https://seekingalpha.com/news/3445377-cetvplus-6_9-on-strategic-alternatives-exploration\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445376\" data-ts=\"1553522987\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445376-googles-stadia-doesnt-amd-cpu\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Google&#39;s Stadia doesn&#39;t have AMD CPU</a></h4><ul><li>Google's (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet Inc.'>GOOG</a> <font color=\"red\">-0.6%</font>)(<a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet Inc.'>GOOGL</a> <font color=\"red\">-0.5%</font>) Stadia streaming product doesn't use AMD's (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) Ryzen or Epyc CPU, <a href=\"https://www.pcgamesn.com/stadia/google-stadia-release-date-price-performance\" target=\"_blank\">PCGamesN confirms</a> with AMD.</li><li>At the initial Stadia launch, Google made it clear that AMD was supplying a custom GPU. But the company was vague on the CPU details either because the decision was made at the last minute or Google plans to include AMD with Intel (NASDAQ:<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a>) at a later date.</li><li>AMD shares are <font color=\"red\">down 1%</font> to $26.12.</li><li>Update: Post updated with link to the PCGamesN piece with more details including AMD's confirmation its CPU's aren't in Stadia at this time.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445376\" data-linked=\"Google&#39;s Stadia doesn&#39;t have AMD CPU\" data-tweet=\"$GOOG $GOOGL $AMD - Google&#39;s Stadia doesn&#39;t have AMD CPU https://seekingalpha.com/news/3445376-googles-stadia-doesnt-amd-cpu?source=tweet\" data-url=\"https://seekingalpha.com/news/3445376-googles-stadia-doesnt-amd-cpu\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>178&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445371\" data-ts=\"1553522793\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRIO\" target=\"_blank\">DRIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445371-dariohealth-slips-14-post-q4-revenue-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DarioHealth slips 14% post Q4 revenue miss</a></h4><ul><li>DarioHealth (<a href='https://seekingalpha.com/symbol/DRIO' title='DarioHealth Corp.'>DRIO</a> <font color=\"red\">-14.8%</font>) reported Q4 revenue growth of 7.7% Y/Y to $1.7M, and Non-GAAP billings of $2.05M (+30% Y/Y).</li><li>During the quarter company recorded $351k of deferred revenues.</li><li>Q4 Gross profit decreased by 61% Y/Y to $223k.</li><li>Operating loss increased by 64.5% Y/Y to $5.1M, reflecting increase in operating expenses.</li><li>Net loss attributable to holders of common stock was $5M, compared to $3.3M a year ago.</li><li>Net cash used in operating activities YTD was $11.47M compared to $10.62M a year ago.</li><li>Company had cash and cash equivalents of $11M, as of December 31, 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3445265-dariohealth-misses-revenue\" target=\"_blank\">DarioHealth misses on revenue</a> (March 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3445371\" data-linked=\"DarioHealth slips 14% post Q4 revenue miss\" data-tweet=\"$DRIO - DarioHealth slips 14% post Q4 revenue miss https://seekingalpha.com/news/3445371-dariohealth-slips-14-post-q4-revenue-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3445371-dariohealth-slips-14-post-q4-revenue-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445372\" data-ts=\"1553522609\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORLY\" target=\"_blank\">ORLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445372-oreilly-auto-added-to-analyst-focus-list-j-p-morgan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">O&#39;Reilly Auto added to Analyst Focus List at J.P. Morgan</a></h4><ul><li>O'Reilly Automotive (<a href='https://seekingalpha.com/symbol/ORLY' title='O&#39;Reilly Automotive, Inc.'>ORLY</a> <font color='green'>+1.8%</font>) is higher after the stock is <a href=\"https://thefly.com/thestreet/realmoney/index.php/ORLY;AAP;AZO;GPCid2883510/ORLY;AAP;AZO;GPC-OReilly-Automotive-added-to-Analyst-Focus-List-at-JPMorgan\" target=\"_blank\">added to J.P. Morgan's Analyst Focus List</a>, as Christopher Horvers says colder weather in areas of O'Reilly shops will benefit it more than Advance Auto Parts (<a href='https://seekingalpha.com/symbol/AAP' title='Advance Auto Parts, Inc.'>AAP</a> <font color='green'>+0.9%</font>), AutoZone (<a href='https://seekingalpha.com/symbol/AZO' title='AutoZone, Inc.'>AZO</a> <font color='green'>+0.9%</font>) and Genuine Parts (<a href='https://seekingalpha.com/symbol/GPC' title='Genuine Parts Company'>GPC</a> <font color='green'>+0.3%</font>) as the harsh winter causes more auto repairs.</li><li>Winter 2019 has been solid but not as good as 2018 due to snowfall levels, Horvers says, noting auto parts demand is \"quite sensitive\" to extreme weather trends.</li><li>Horvers keeps his Overweight rating and $398 price target on ORLY shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445372\" data-linked=\"O&#39;Reilly Auto added to Analyst Focus List at J.P. Morgan\" data-tweet=\"$ORLY $AAP $AZO - O&#39;Reilly Auto added to Analyst Focus List at J.P. Morgan https://seekingalpha.com/news/3445372-oreilly-auto-added-to-analyst-focus-list-j-p-morgan?source=tweet\" data-url=\"https://seekingalpha.com/news/3445372-oreilly-auto-added-to-analyst-focus-list-j-p-morgan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445365\" data-ts=\"1553521738\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASND\" target=\"_blank\">ASND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445365-ascendis-pharma-up-2-on-positive-transcon-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ascendis Pharma up 2% on positive TransCon data</a></h4><ul><li>Ascendis Pharma A/S (<a href='https://seekingalpha.com/symbol/ASND' title='Ascendis Pharma A/S'>ASND</a> <font color=\"green\">+1.6%</font>) is up on light volume in response to positive <a href=\"https://seekingalpha.com/pr/17453218-ascendis-pharma-announces-phase-3-height-trial-demonstrated-superior-efficacy-comparable\" target=\"_blank\">topline results</a> from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02781727?spons=ascendis&amp;phase=2&amp;rank=3\" target=\"_blank\">heiGHt</a>, evaluating TransCon Growth Hormone in children with growth hormone deficiency. The data were presented at the Endocrine Society Annual Meeting in New Orleans.</li><li>Participants receiving once-weekly TransCon experienced similar safety and tolerability to once-daily doses of Pfizer's (<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color=\"red\">-0.1%</font>) <a href=\"https://www.genotropin.com/\" target=\"_blank\">Genotropin </a>(somatropin) with greater increases in annualized height velocity &#40;AHV&#41; over the one-year treatment period. Specifically, patients in the TransCon cohort showed an AHV of 11.2 cm/year compared to 10.3 cm/year in the Genotropin cohort, a statistically significant difference (p=0.0088).</li><li>The proportion of poor responders (AHV less than 8.0 cm/year) was 4% in the TransCon group versus 11% in the Genotropin group.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445365\" data-linked=\"Ascendis Pharma up 2% on positive TransCon data\" data-tweet=\"$ASND $ASND $PFE - Ascendis Pharma up 2% on positive TransCon data https://seekingalpha.com/news/3445365-ascendis-pharma-up-2-on-positive-transcon-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3445365-ascendis-pharma-up-2-on-positive-transcon-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445353\" data-ts=\"1553520567\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IRDM\" target=\"_blank\">IRDM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445353-iridiumplus-2_7-after-cramer-appearance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Iridium +2.7% after Cramer appearance</a></h4><ul>   <li>Iridium Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/IRDM' title='Iridium Communications Inc.'>IRDM</a>) drew some attention on Jim Cramer's <i>Mad Money,</i> where CEO Matt Desch appeared.</li>    <li>In Cramer's look at the week ahead, Desch discussed the status of the company's NEXT satellite constellation, now <a href=\"https://seekingalpha.com/news/3422503-iridium-plus-7_5-percent-last-10-next-satellites-delivered-orbit\" target=\"_blank\">completed and in orbit</a> as of January.</li>    <li>NEXT support will be installed by every airline operating in the U.S. and Europe by the end of the year, Desch said.</li>    <li>Shares are <font color=\"green\">up 2.7%</font> premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3445353\" data-linked=\"Iridium +2.7% after Cramer appearance\" data-tweet=\"$IRDM - Iridium +2.7% after Cramer appearance https://seekingalpha.com/news/3445353-iridiumplus-2_7-after-cramer-appearance?source=tweet\" data-url=\"https://seekingalpha.com/news/3445353-iridiumplus-2_7-after-cramer-appearance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445351\" data-ts=\"1553520415\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBBP\" target=\"_blank\">SBBP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445351-strongbridge-bio-up-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Strongbridge Bio up 8% premarket</a></h4><ul><li>Strongbridge Biopharma (NASDAQ:<a href='https://seekingalpha.com/symbol/SBBP' title='Strongbridge Biopharma plc'>SBBP</a>) is up <font color=\"green\">8%</font> premarket on light volume on the heels of new <a href=\"https://seekingalpha.com/pr/17453466-strongbridge-biopharma-plc-announces-presentation-new-data-analyses-phase-3-sonics-study\" target=\"_blank\">analyses </a>from the open-label Phase 3 SONICS study of RECORLEV (levoketoconazole) in patients with <a href=\"https://www.mayoclinic.org/diseases-conditions/cushing-syndrome/symptoms-causes/syc-20351310\" target=\"_blank\">Cushing's disease</a>, a metabolic disorder characterized by excess amounts of the hormone cortisol. The data were presented at the Endocrine Society Annual Meeting in New Orleans.</li><li>Patients receiving RECORLEV experienced sustained reductions in both mean urinary-free cortisol (mUFC) and late-night salivary cortisol &#40;LNSC&#41; levels over a six-month maintenance treatment period.</li><li>ACTH levels in a subset of treated patients almost doubled during the maintenance phase.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445351\" data-linked=\"Strongbridge Bio up 8% premarket\" data-tweet=\"$SBBP - Strongbridge Bio up 8% premarket https://seekingalpha.com/news/3445351-strongbridge-bio-up-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3445351-strongbridge-bio-up-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445345\" data-ts=\"1553519908\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445345-cris-asna-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CRIS, ASNA among premarket gainers</a></h4><ul><li>Curis (NASDAQ:<a href='https://seekingalpha.com/symbol/CRIS' title='Curis, Inc.'>CRIS</a>) <font color=\"green\">+74%</font> on <a href=\"https://seekingalpha.com/pr/17453679-curis-sells-portion-erivedge-royalties-oberland-capital-135_7-million\" target=\"_blank\">selling</a> Portion of Erivedge Royalties to Oberland Capital for up to $135.7M.</li><li>The9 (NASDAQ:<a href='https://seekingalpha.com/symbol/NCTY' title='The9 Limited'>NCTY</a>) <font color=\"green\">+67%</font> on JV <a href=\"https://seekingalpha.com/pr/17453227-the9-limited-signs-joint-venture-agreement-faraday-and-future-inc\" target=\"_blank\">agreement</a> with Faraday&amp;Future.</li><li>Avaya Holdings (NYSE:<a href='https://seekingalpha.com/symbol/AVYA' title='Avaya Holdings Corp.'>AVYA</a>) <font color=\"green\">+32%</font> on leveraged buyout <a href=\"https://seekingalpha.com/news/3445304-avaya-plus-27-percent-leveraged-buyout-talks-reuters\" target=\"_blank\">talks</a>.</li><li>Ascena Retail (NASDAQ:<a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group, Inc.'>ASNA</a>) <font color=\"green\">+12%</font> on <a href=\"https://seekingalpha.com/news/3445336-ascena-plus-11-percent-300m-deal-sell-stake-maurices-clothing-chain\" target=\"_blank\">selling</a> stake in Maurices clothing chain for $300M.</li><li>Axsome Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics, Inc.'>AXSM</a>) <font color=\"green\">+9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445345\" data-linked=\"CRIS, ASNA among premarket gainers\" data-tweet=\"$CRIS $NCTY $AVYA - CRIS, ASNA among premarket gainers https://seekingalpha.com/news/3445345-cris-asna-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3445345-cris-asna-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445343\" data-ts=\"1553519641\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTDR\" target=\"_blank\">FTDR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445343-frontdoorplus-1_7-on-pair-of-strong-initiations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Frontdoor +1.7% on pair of strong initiations</a></h4><ul><li>Wells Fargo initiates Frontdoor (NASDAQ:<a href='https://seekingalpha.com/symbol/FTDR' title='frontdoor, inc.'>FTDR</a>) with an Outperform rating and a $40 PT, implying a 22% upside.</li><li>JPMorgan starts FTDR at Overweight and a $41 target.</li><li>Last month, the company <a href=\"https://seekingalpha.com/news/3437829-frontdoor-plus-16-percent-guidance-satisfies\" target=\"_blank\">reported earnings</a> with a full-year revenue guidance that beat consensus estimates.</li><li>Last week, Frontdoor <a href=\"https://seekingalpha.com/news/3444673-frontdoor-prices-secondary-offering-remaining-shares-held-servicemaster\" target=\"_blank\">priced</a> a secondary offering of the remaining shares held by ServiceMaster.</li><li>Frontdoor shares are <font color=\"green\">up 1.7%</font> pre-market to $33.25.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445343\" data-linked=\"Frontdoor +1.7% on pair of strong initiations\" data-tweet=\"$FTDR - Frontdoor +1.7% on pair of strong initiations https://seekingalpha.com/news/3445343-frontdoorplus-1_7-on-pair-of-strong-initiations?source=tweet\" data-url=\"https://seekingalpha.com/news/3445343-frontdoorplus-1_7-on-pair-of-strong-initiations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445342\" data-ts=\"1553519636\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRIS\" target=\"_blank\">CRIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445342-curis-up-73-on-sale-of-portion-of-erivedge-royalties\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Curis up 73% on sale of portion of Erivedge royalties</a></h4><ul><li>Thinly traded nano cap Curis (NASDAQ:<a href='https://seekingalpha.com/symbol/CRIS' title='Curis, Inc.'>CRIS</a>) is up <font color=\"green\">73%</font> premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/17453679-curis-sells-portion-erivedge-royalties-oberland-capital-135_7-million\" target=\"_blank\">agreement </a>to sale of a portion of global royalties from Erivedge (vismodegib) for up to $135.7M to Oberland Capital Management, LLC.</li><li>Under the terms of the deal, Curis will receive $65M upfront and up to $70.7M in milestones if certain annual and cumulative sales targets are achieved. Oberland will receive all of the first $13.2M of global royalties and 35% thereafter, exclusive of a portion of U.S. royalties retained by Curis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445342\" data-linked=\"Curis up 73% on sale of portion of Erivedge royalties\" data-tweet=\"$CRIS - Curis up 73% on sale of portion of Erivedge royalties https://seekingalpha.com/news/3445342-curis-up-73-on-sale-of-portion-of-erivedge-royalties?source=tweet\" data-url=\"https://seekingalpha.com/news/3445342-curis-up-73-on-sale-of-portion-of-erivedge-royalties\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445341\" data-ts=\"1553519608\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445341-healthcare-stocks-stand-out-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare stocks stand out among premarket losers</a></h4><ul><li>Proteostasis Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics, Inc.'>PTI</a>) <font color=\"red\">-56%</font> on <a href=\"https://seekingalpha.com/news/3445329-proteostasis-48-percent-premarket-disappointing-data-cf-candidates\" target=\"_blank\">disappointing</a> data on CF candidates.</li><li>Recro Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/REPH' title='Recro Pharma, Inc.'>REPH</a>) <font color=\"red\">-43%</font> on <a href=\"https://seekingalpha.com/news/3445318-recro-pharma-45-percent-second-crl-iv-meloxicam\" target=\"_blank\">second</a> CRL for IV meloxicam.</li><li>Motif Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/MTFB' title='Motif Bio plc'>MTFB</a>) <font color=\"red\">-12%</font>.</li><li>Electrameccanica Vehicles (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLO' title='Electrameccanica Vehicles Corp.'>SOLO</a>) <font color=\"red\">-12%</font>.</li><li>One Stop Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/OSS' title='One Stop Systems, Inc.'>OSS</a>) <font color=\"red\">-10%</font>.</li><li>Sorrento Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a>) <font color=\"red\">-9%</font>.</li><li>Bio-Path Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a>) <font color=\"red\">-9%</font>.</li><li>Immutep (NASDAQ:<a href='https://seekingalpha.com/symbol/IMMP' title='Immutep Limited'>IMMP</a>) <font color=\"red\">-8%</font>.</li><li>Pain Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTIE' title='Pain Therapeutics, Inc.'>PTIE</a>) <font color=\"red\">-8%</font> on <a href=\"https://seekingalpha.com/news/3445331-pain-therapeutics-reports-q4-results\" target=\"_blank\">Q4 results</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3445341\" data-linked=\"Healthcare stocks stand out among premarket losers\" data-tweet=\"$PTI $REPH $MTFB - Healthcare stocks stand out among premarket losers https://seekingalpha.com/news/3445341-healthcare-stocks-stand-out-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3445341-healthcare-stocks-stand-out-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445336\" data-ts=\"1553518957\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASNA\" target=\"_blank\">ASNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445336-ascenaplus-11-on-300m-deal-to-sell-stake-in-maurices-clothing-chain\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ascena +11% on $300M deal to sell stake in Maurices clothing chain</a></h4><ul><li>Ascena Retail (NASDAQ:<a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group, Inc.'>ASNA</a>) <font color=\"green\">+11.2%</font> pre-market after <a href=\"https://seekingalpha.com/pr/17453647-ascena-retail-group-signs-definitive-agreement-sell-majority-stake-maurices-brand\" target=\"_blank\">agreeing to sell</a> a majority interest in its Maurices women's clothing subsidiary to P-E firm OpCapita for ~$300M.</li><li>ASNA says the move is part of its portfolio review plan that is on track to deliver run-rate cost savings of $300M by this July, with plans for an additional $150M in savings intended to drive operating margin expansion.</li><li>ASNA says it will continue to support the Maurices brand on its shared business services platform through a managed services agreement, including support for IT, supply chain, sourcing and certain back office functions.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445336\" data-linked=\"Ascena +11% on $300M deal to sell stake in Maurices clothing chain\" data-tweet=\"$ASNA - Ascena +11% on $300M deal to sell stake in Maurices clothing chain https://seekingalpha.com/news/3445336-ascenaplus-11-on-300m-deal-to-sell-stake-in-maurices-clothing-chain?source=tweet\" data-url=\"https://seekingalpha.com/news/3445336-ascenaplus-11-on-300m-deal-to-sell-stake-in-maurices-clothing-chain\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445335\" data-ts=\"1553518950\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOXA\" target=\"_blank\">FOXA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445335-jpmorgan-initiates-fox-overweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan initiates Fox at &#39;Overweight&#39;</a></h4><ul><li>\"We are <a href=\"https://www.cnbc.com/2019/03/25/calls-of-the-day-tesla-oreilly-automotive-fox--more.html\" target=\"_blank\">initiating</a> coverage of FOX Corporation with an Overweight rating and a December 2019 price target of $46. FOXA has an impressive mix of businesses, including strong cable channels driven by live news and sports, as well as a major broadcast network with a leading local TV footprint.\"</li><li>\"We believe FOXA shares will maintain a premium valuation over the average in our large-cap media universe due to its higher growth profile, implying notable upside to shares from the current level.\"</li><li><a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color=\"green\">+0.7%</font>; <a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color=\"green\">+1.3%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3445335\" data-linked=\"JPMorgan initiates Fox at &#39;Overweight&#39;\" data-tweet=\"$FOXA $FOX - JPMorgan initiates Fox at &#39;Overweight&#39; https://seekingalpha.com/news/3445335-jpmorgan-initiates-fox-overweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3445335-jpmorgan-initiates-fox-overweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445330\" data-ts=\"1553518466\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445330-foxplus-1_4-on-overweight-start\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fox +1.4% on Overweight start</a></h4><ul><li>JPMorgan initiates Fox ([FOX],[FOXB]) at Overweight with a $48 target citing \"an impressive mix of businesses, including strong cable channels driven by live news and sports.\"</li><li>The firm thinks Fox shares will \"maintain a premium valuation over the average in our large-cap media universe due to its higher growth profile.\"</li><li>Fox shares are up 1.4% pre-market to $37.98.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445330\" data-linked=\"Fox +1.4% on Overweight start\" data-tweet=\"Fox +1.4% on Overweight start https://seekingalpha.com/news/3445330-foxplus-1_4-on-overweight-start?source=tweet\" data-url=\"https://seekingalpha.com/news/3445330-foxplus-1_4-on-overweight-start\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445329\" data-ts=\"1553518168\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTI\" target=\"_blank\">PTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445329-proteostasis-down-48-premarket-on-disappointing-data-on-cf-candidates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Proteostasis down 48% premarket on disappointing data on CF candidates</a></h4><ul><li>Proteostasis Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics, Inc.'>PTI</a>) slumps <font color=\"red\">48%</font> premarket on increased volume on the heels of its <a href=\"https://seekingalpha.com/pr/17453429-proteostasis-therapeutics-announces-broad-new-dataset-proprietary-combination-add-cftr\" target=\"_blank\">announcement</a> of Phase 1 data on cystic fibrosis &#40;CF&#41; triplet therapy of PTI-801 (CFTR corrector), PTI-808 (CFTR potentiator) and PTI-428 (CFTR amplifier) and separate studies of PTI-801 and PTI-428 as add-on therapies to background tezacaftor/ivacaftor [Vertex Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a>) Symdeko].</li><li>The triplet therapy failed to demonstrate a significant treatment benefit at day 14 as determined by a measure of lung function called ppFEV1. A dose-dependent improvement in ppFEV1 and sweat chloride &#40;SC&#41; was observed in patients receiving PTI-801.</li><li>The company says it plans to evaluate optimal doses of PTI-801 and PTI-808 in longer duration studies in CF patients \"who are not predisposed to rapid pulmonary decline.\" The trials should wind up by year-end with preliminary data available thereafter.</li><li>It plans to launch three new 28-day Phase 2 trials in CF patients with at least one F508del mutation this year for the triplet therapy and 801/808 combo therapies. It maintains its expectation that Phase 3 development will launch in mid-2020.</li><li>VRTX is up <font color=\"green\">2%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445329\" data-linked=\"Proteostasis down 48% premarket on disappointing data on CF candidates\" data-tweet=\"$PTI $PTI $VRTX - Proteostasis down 48% premarket on disappointing data on CF candidates https://seekingalpha.com/news/3445329-proteostasis-down-48-premarket-on-disappointing-data-on-cf-candidates?source=tweet\" data-url=\"https://seekingalpha.com/news/3445329-proteostasis-down-48-premarket-on-disappointing-data-on-cf-candidates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445326\" data-ts=\"1553517612\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445326-rbc-lowers-pt-on-tesla-cuts-model-3-forecast\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RBC lowers PT on Tesla, cuts Model 3 forecast</a></h4><ul><li>Lackluster demand and overseas Model 3 delivery problems will <a href=\"https://www.cnbc.com/2019/03/25/rbc-cuts-tesla-price-target-model-3-deliveries.html\" target=\"_blank\">weigh</a> on Tesla's (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) Q1 results, according to a new warning from RBC Capital.</li><li>The brokerage reiterated its Underperform rating on shares and slashed its price target to $210 from $245, a 14% reduction that implies more than 20% downside over the next year.</li><li>RBC Capital also cut its first-quarter Model 3 delivery forecast to 52,500 from 57,000, while for 2019 it \"forecast about 261,000 Model 3 [deliveries], down from 268,000 prior. Our 2020 forecast of 347,500 remains unchanged.\"</li><li>TSLA <font color=\"red\">-2.3%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3445326\" data-linked=\"RBC lowers PT on Tesla, cuts Model 3 forecast\" data-tweet=\"$TSLA - RBC lowers PT on Tesla, cuts Model 3 forecast https://seekingalpha.com/news/3445326-rbc-lowers-pt-on-tesla-cuts-model-3-forecast?source=tweet\" data-url=\"https://seekingalpha.com/news/3445326-rbc-lowers-pt-on-tesla-cuts-model-3-forecast\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>314&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445325\" data-ts=\"1553517394\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ON\" target=\"_blank\">ON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445325-on-semiminus-1_5-worst-risk-of-semis-morgan-stanley\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ON Semi -1.5% as worst risk of semis - Morgan Stanley</a></h4><ul><li>Morgan Stanley says ON Semi (NASDAQ:<a href='https://seekingalpha.com/symbol/ON' title='ON Semiconductor Corporation'>ON</a>) has the \"most unattractive\" risk profile in its coverage universe.</li><li>The firm sees sees positive sentiment around \"structural\" improvement as \"misplaced considering our view that the cycle for ON has yet to even bottom and risks to estimates remain elevated.\"</li><li>Analyst Craig Hettenbach expects H2 to \"prove disappointing relative to growing optimism about a recovery\" and that's \"especially the case for ON.\"</li><li>Rating and target reiterated at Underweight and the Street-low $14.50.</li><li>ON shares are <font color=\"red\">down 1.5%</font> pre-market to $21.31.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445325\" data-linked=\"ON Semi -1.5% as worst risk of semis - Morgan Stanley\" data-tweet=\"$ON - ON Semi -1.5% as worst risk of semis - Morgan Stanley https://seekingalpha.com/news/3445325-on-semiminus-1_5-worst-risk-of-semis-morgan-stanley?source=tweet\" data-url=\"https://seekingalpha.com/news/3445325-on-semiminus-1_5-worst-risk-of-semis-morgan-stanley\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445318\" data-ts=\"1553516804\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REPH\" target=\"_blank\">REPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445318-recro-pharma-down-45-on-second-crl-for-iv-meloxicam\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Recro Pharma down 45% on second CRL for IV meloxicam</a></h4><ul><li>Thinly traded micro cap Recro Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/REPH' title='Recro Pharma, Inc.'>REPH</a>) slumps <font color=\"red\">45% </font>premarket on light volume on the heels of its second <a href=\"https://seekingalpha.com/news/3445184-fda-rejects-recro-pharmas-iv-meloxicam\" target=\"_blank\">Complete Response Letter</a> &#40;CRL&#41; from the FDA regarding IV meloxicam.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445318\" data-linked=\"Recro Pharma down 45% on second CRL for IV meloxicam\" data-tweet=\"$REPH - Recro Pharma down 45% on second CRL for IV meloxicam https://seekingalpha.com/news/3445318-recro-pharma-down-45-on-second-crl-for-iv-meloxicam?source=tweet\" data-url=\"https://seekingalpha.com/news/3445318-recro-pharma-down-45-on-second-crl-for-iv-meloxicam\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445316\" data-ts=\"1553516563\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VALE\" target=\"_blank\">VALE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445316-vale-says-brazil-mining-dams-stability-in-critical-condition\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vale says Brazil mining dam&#39;s stability in critical condition</a></h4><ul><li>Vale (NYSE:<a href='https://seekingalpha.com/symbol/VALE' title='Vale S.A.'>VALE</a>) <font color=\"red\">-2.3%</font> pre-market after saying the stability of the Sul Superior Dam at its Gongo Soco mine in Brazil's Minas Gerais state is <a href=\"http://www.mining.com/vales-sul-superior-dam-critical-condition/\" target=\"_blank\">in a critical condition</a>, citing the work of an independent  auditor.</li><li>It is the same region of the January 2019 dam collapse at Vale\u2019s Córrego do Feijão iron ore mine that killed hundreds of people and caused massive environmental destruction.</li><li>In an effort to avoid a similar tragedy, Vale says it has launched a protocol to initiate a level 3 alert of the Mining Dams Emergency Action Plan for Sul Superior, which is  inactive and is scheduled to be decommissioned together with other nine dams.</li><li>Separately, Vale says a Brazilian court has issued an injunction <a href=\"https://www.reuters.com/article/us-vale-sa-disaster/court-halts-operations-at-13-vale-dams-operations-at-major-mine-affected-idUSKCN1R61AC\" target=\"_blank\">halting operations at 13 of its tailings dams</a>, which will delay production at its Brucutu mine.</li><li>Minas Gerais authorities last week authorized Vale to restart operations at Brucutu after halting operations there in early February.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445316\" data-linked=\"Vale says Brazil mining dam&#39;s stability in critical condition\" data-tweet=\"$VALE - Vale says Brazil mining dam&#39;s stability in critical condition https://seekingalpha.com/news/3445316-vale-says-brazil-mining-dams-stability-in-critical-condition?source=tweet\" data-url=\"https://seekingalpha.com/news/3445316-vale-says-brazil-mining-dams-stability-in-critical-condition\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445315\" data-ts=\"1553516541\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIMT\" target=\"_blank\">AIMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445315-aimmune-up-9-premarket-on-successful-ar101-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aimmune up 9% premarket on successful AR101 study</a></h4><ul><li>Aimmune Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AIMT' title='Aimmune Therapeutics, Inc.'>AIMT</a>) is up <font color=\"green\">9%</font> premarket on light volume in response to <a href=\"https://seekingalpha.com/pr/17453561-european-phase-3-trial-aimmune-therapeutics-ar101-meets-primary-endpoint\" target=\"_blank\">successful result</a>s from a European Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03201003?titles=artemis&amp;lead=aimmune&amp;phase=2&amp;rank=1\" target=\"_blank\">ARTEMIS</a>, evaluating lead candidate AR101 for the treatment of peanut allergy.</li><li>The study met the primary endpoint of a statistically significant proportion of AR101-treated patients who tolerated a 1 g dose of peanut protein in a blinded exit challenge at month 9 compared to placebo (p&lt;0.00001).</li><li>The median tolerated dose of peanut protein in the treatment group improved 100-fold (10 mg at baseline to 1,000 mg at exit).</li><li>No new safety signals were reported.</li><li>The company plans to file a marketing application in Europe mid-year. Its U.S. marketing application is currently under FDA review with an expected action date around January 2020.</li><li>Management will host a conference call this morning at 8:30 am to discuss the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445315\" data-linked=\"Aimmune up 9% premarket on successful AR101 study\" data-tweet=\"$AIMT - Aimmune up 9% premarket on successful AR101 study https://seekingalpha.com/news/3445315-aimmune-up-9-premarket-on-successful-ar101-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3445315-aimmune-up-9-premarket-on-successful-ar101-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445314\" data-ts=\"1553516505\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HON\" target=\"_blank\">HON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445314-deutsche-bank-buy-honeywell-sell-3m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deutsche Bank: Buy Honeywell, sell 3M</a></h4><ul><li>A short-term \"Catalyst Call\" by Deutsche Bank analyst Nicole DeBlase is suggesting investors buy shares of Honeywell (NYSE:<a href='https://seekingalpha.com/symbol/HON' title='Honeywell International Inc.'>HON</a>) and sell 3M (NYSE:<a href='https://seekingalpha.com/symbol/MMM' title='3M Company'>MMM</a>).</li><li>He cited continued potential for positive quarterly results from Honeywell given its \"attractive exposure\" to late-cycle end markets, but forecast a \"substantial\" 4% earnings miss in the first quarter for 3M due to a number of end markets that have experienced deterioration.</li><li>Honeywell PT <a href=\"https://www.streetinsider.com/Analyst+PT+Change/Honeywell+International+%28HON%29+PT+Raised+to+%24174+at+Deutsche+Bank%2C+Added+as+Short+Term+Catalyst+Call/15291908.html\" target=\"_blank\">raised</a> to $174; 3M PT <a href=\"https://www.streetinsider.com/Analyst+Comments/3M+%28MMM%29+PT+Lowered+to+%24188+at+Deutsche+Bank%2C+Added+as+Short-Term+Catalyst+Call/15291894.html\" target=\"_blank\">lowered</a> to $188.</li><li>MMM <font color=\"red\">-0.7%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3445314\" data-linked=\"Deutsche Bank: Buy Honeywell, sell 3M\" data-tweet=\"$HON $MMM - Deutsche Bank: Buy Honeywell, sell 3M https://seekingalpha.com/news/3445314-deutsche-bank-buy-honeywell-sell-3m?source=tweet\" data-url=\"https://seekingalpha.com/news/3445314-deutsche-bank-buy-honeywell-sell-3m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445309\" data-ts=\"1553515926\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIIB\" target=\"_blank\">BIIB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445309-biogen-boosts-buyback-shares-up-1_5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biogen boosts buyback; shares up 1.5%</a></h4><ul><li>In the wake of last week's aducanumab-related plunge, Biogen (NASDAQ:<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a>) this morning <a href=\"https://seekingalpha.com/filing/4416456\" target=\"_blank\">announces a $5B addition</a> to its buyback program.</li><li>There remains $1.7B under the previous repurchase plan.</li><li>Shares <font color=\"green\">+1.5%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3445309\" data-linked=\"Biogen boosts buyback; shares up 1.5%\" data-tweet=\"$BIIB - Biogen boosts buyback; shares up 1.5% https://seekingalpha.com/news/3445309-biogen-boosts-buyback-shares-up-1_5?source=tweet\" data-url=\"https://seekingalpha.com/news/3445309-biogen-boosts-buyback-shares-up-1_5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445304\" data-ts=\"1553515437\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVYA\" target=\"_blank\">AVYA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445304-avayaplus-27-on-leveraged-buyout-talks-reuters\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Avaya +27% on leveraged buyout talks - Reuters</a></h4><ul><li>Avaya Holdings (NYSE:<a href='https://seekingalpha.com/symbol/AVYA' title='Avaya Holdings Corp.'>AVYA</a>) gains 27.2% pre-market after yesterday's <a href=\"https://www.reuters.com/article/us-avaya-hldg-m-a-exclusive/exclusive-telecom-equipment-provider-avaya-considers-leveraged-buyout-sources-idUSKCN1R50PR\" target=\"_blank\">Reuters report</a> that the company is considering a leveraged buyout with an over $5B value, including debt.</li><li>The company emerged from bankruptcy protection 15 months ago after a previous leveraged buyout, an $8.3B sale to TPG Capital and Silver Lake in 2007.</li><li>The board is considering an offer from an unnamed PE firm that stands at over $20 per share. Avaya's debt was $3.2B at the end of December.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445304\" data-linked=\"Avaya +27% on leveraged buyout talks - Reuters\" data-tweet=\"$AVYA - Avaya +27% on leveraged buyout talks - Reuters https://seekingalpha.com/news/3445304-avayaplus-27-on-leveraged-buyout-talks-reuters?source=tweet\" data-url=\"https://seekingalpha.com/news/3445304-avayaplus-27-on-leveraged-buyout-talks-reuters\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445303\" data-ts=\"1553515409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRPT\" target=\"_blank\">SRPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445303-sarepta-up-4-premarket-on-gene-therapy-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sarepta up 4% premarket on gene therapy update</a></h4><ul><li>Sarepta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>) is up <font color=\"green\">4%</font> premarket on light volume as its <a href=\"https://seekingalpha.com/pr/17453473-sarepta-therapeutics-provide-update-duchenne-muscular-dystrophy-gene-therapy-program\" target=\"_blank\">conference call</a> gets underway this morning to update investors on its Phase 1 open-label study of its micro-dystrophin gene therapy for Duchenne muscular dystrophy &#40;DMD&#41;. The company says functional  and creatine kinase data at month 9 for the four participants are \"encouraging.\"</li><li><strong>Update</strong>: In its <a href=\"https://www.sec.gov/Archives/edgar/data/873303/000119312519084354/d691983dex991.htm\" target=\"_blank\">slide presentation</a>, all four treated patients showed increased micro-dystrophin expression in calf muscle fibers at day 90 (mean 81.2%). All patients are doing well. Biomarkers showed large magnitude of effect within three months. Initial functional data showed consistent and sustained improvement from baseline to day 270.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445303\" data-linked=\"Sarepta up 4% premarket on gene therapy update\" data-tweet=\"$SRPT - Sarepta up 4% premarket on gene therapy update https://seekingalpha.com/news/3445303-sarepta-up-4-premarket-on-gene-therapy-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3445303-sarepta-up-4-premarket-on-gene-therapy-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445294\" data-ts=\"1553514773\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LPSN\" target=\"_blank\">LPSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445294-piper-starts-liveperson-overweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Piper starts LivePerson at Overweight</a></h4><ul><li>Piper Jaffray initiates LivePerson (NASDAQ:<a href='https://seekingalpha.com/symbol/LPSN' title='LivePerson, Inc.'>LPSN</a>) at Overweight with a $39 target, implying a 38% upside.</li><li>Earlier this month, Barclays <a href=\"https://seekingalpha.com/news/3441097-barclays-starts-liveperson-28-percent-upside\" target=\"_blank\">started</a> LivePerson at Overweight and Evercore started at Outperform citing the company's position to benefit from broad digital transformation trends.</li><li>LPSN is <font color=\"green\">up 0.8%</font> pre-market to $28.44.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445294\" data-linked=\"Piper starts LivePerson at Overweight\" data-tweet=\"$LPSN - Piper starts LivePerson at Overweight https://seekingalpha.com/news/3445294-piper-starts-liveperson-overweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3445294-piper-starts-liveperson-overweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445292\" data-ts=\"1553514304\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TXN\" target=\"_blank\">TXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445292-texas-instrumentsminus-1_5-on-bernstein-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Texas instruments -1.5% on Bernstein downgrade</a></h4><ul><li>Bernstein cuts Texas Instruments (NASDAQ:<a href='https://seekingalpha.com/symbol/TXN' title='Texas Instruments Incorporated'>TXN</a>) from Outperform to Market Perform with a $115 target, implying a 5% upside.</li><li>Semi names<a href=\"https://seekingalpha.com/news/3444869-semis-gain-microns-forecast\" target=\"_blank\"> got a boost</a> last week from Micron's <a href=\"https://seekingalpha.com/news/3444601-micron-plus-2_2-percent-q2-beats-capex-cut\" target=\"_blank\">earnings report</a>, which included weak guidance due to the DRAM crash but forecast a H2 2019 memory market recovery.</li><li>TXN is <font color=\"red\">down 1.5%</font> pre-market to $108.02.</li><li>Update with details from the research note:</li><li>The firm says that it's becoming \"increasingly nervous about the set-up for the industry into the 2H (with inventories remaining elevated, expectations higher, and valuations less favorable).\"</li><li>After the recent run, Bernstein steps to the sidelines on TXN and ADI seeing those as \"more broadly exposed, and more expensive.\"</li><li>But the firm says it \"wouldn't talk anyone out of owning either for the long term.\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3445276-bernstein-steps-aside-analog-devices\" target=\"_blank\">Bernstein steps aside on Analog Devices</a> (March 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3445292\" data-linked=\"Texas instruments -1.5% on Bernstein downgrade\" data-tweet=\"$TXN - Texas instruments -1.5% on Bernstein downgrade https://seekingalpha.com/news/3445292-texas-instrumentsminus-1_5-on-bernstein-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3445292-texas-instrumentsminus-1_5-on-bernstein-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445291\" data-ts=\"1553514297\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APTO\" target=\"_blank\">APTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445291-fda-accepts-aptoses-ind-for-cgminus-806-shares-up-10-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Aptose&#39;s IND for CG-806; shares up 10% premarket</a></h4><ul> <li>The FDA has <a href=\"https://seekingalpha.com/pr/17453438-aptose-announces-fda-allowance-investigational-new-drug-application-cgminus-806\" target=\"_blank\">completed</a> the review of Aptose Biosciences' (NASDAQ:<a href='https://seekingalpha.com/symbol/APTO' title='Aptose Biosciences Inc.'>APTO</a>) IND submission for CG-806. The Company has been granted IND allowance to initiate Phase 1 trial with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas &#40;NHL&#41;.</li>    <li>The trial is expected to initiate in Q2. Pending collection and careful review of the initial safety data, Aptose plans to seek allowance to move into patient populations in a separate Phase 1 trial.</li><li>Shares are up <font color=\"green\">10%</font> premarket.</li>        </ul><div class=\"tiny-share-widget\" data-id=\"3445291\" data-linked=\"FDA accepts Aptose&#39;s IND for CG-806; shares up 10% premarket\" data-tweet=\"$APTO - FDA accepts Aptose&#39;s IND for CG-806; shares up 10% premarket https://seekingalpha.com/news/3445291-fda-accepts-aptoses-ind-for-cgminus-806-shares-up-10-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3445291-fda-accepts-aptoses-ind-for-cgminus-806-shares-up-10-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445288\" data-ts=\"1553514007\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIA\" target=\"_blank\">VIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445288-viacomplus-5-after-renewing-contract-and-t-avoiding-directv-blackout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viacom +5% after renewing contract with AT&amp;T, avoiding DirecTV blackout</a></h4><ul><li>Viacom (<a href='https://seekingalpha.com/symbol/VIA' title='Viacom Inc.'>VIA</a>, <a href='https://seekingalpha.com/symbol/VIAB' title='Viacom Inc.'>VIAB</a>) <font color=\"green\">+5.1%</font> pre-market on news it has <a href=\"https://www.hollywoodreporter.com/news/viacom-at-t-strike-new-carriage-deal-1196779\" target=\"_blank\">renewed its contract</a> with AT&amp;T (NYSE:<a href='https://seekingalpha.com/symbol/T' title='AT&T Inc.'>T</a>), avoiding a blackout of Comedy Central, MTV, Nickelodeon and other channels on the DirectTV service; details are not disclosed.</li><li>The new deal was reached after rhetoric had heated up last week ahead of the expiration of the companies' previous deal.</li><li>AT&amp;T, provides TV service to 24.5M homes in the U.S., was demanding a reduction in the carriage fees charged by Viacom.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445288\" data-linked=\"Viacom +5% after renewing contract with AT&amp;T, avoiding DirecTV blackout\" data-tweet=\"$VIA $VIAB $T - Viacom +5% after renewing contract with AT&amp;T, avoiding DirecTV blackout https://seekingalpha.com/news/3445288-viacomplus-5-after-renewing-contract-and-t-avoiding-directv-blackout?source=tweet\" data-url=\"https://seekingalpha.com/news/3445288-viacomplus-5-after-renewing-contract-and-t-avoiding-directv-blackout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445281\" data-ts=\"1553513274\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAMP\" target=\"_blank\">CAMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445281-calampminus-2-jpmorgan-hits-sidelines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CalAmp -2% as JPMorgan hits sidelines</a></h4><ul><li>JPMorgan downgrades CalAmp (NASDAQ:<a href='https://seekingalpha.com/symbol/CAMP' title='CalAmp Corp.'>CAMP</a>) from Overweight to Neutral and keeps a $17 PT citing limited catalysts.</li><li>The target implies a 39% upside.</li><li>CAMP is<font color=\"red\"> down 2.4%</font> pre-market to $11.95.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445281\" data-linked=\"CalAmp -2% as JPMorgan hits sidelines\" data-tweet=\"$CAMP - CalAmp -2% as JPMorgan hits sidelines https://seekingalpha.com/news/3445281-calampminus-2-jpmorgan-hits-sidelines?source=tweet\" data-url=\"https://seekingalpha.com/news/3445281-calampminus-2-jpmorgan-hits-sidelines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445279\" data-ts=\"1553513051\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WGO\" target=\"_blank\">WGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445279-winnebagos-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More Winnebago&#39;s Q2 results</a></h4><ul><li>Winnebago (NYSE:<a href='https://seekingalpha.com/symbol/WGO' title='Winnebago Industries, Inc.'>WGO</a>) reports Motorhome revenue fell 17.3% to $164.7M in <a href=\"https://seekingalpha.com/pr/17453435-winnebago-industries-announces-second-quarter-fiscal-2019-results\" target=\"_blank\">Q2</a>, driven primarily by a decrease in Class A and Class C unit sales</li><li>Towable revenue declined 5.9% to $50.7M, driven by dealer network efforts to reduce inventory levels and comparing against very strong shipments in the prior year.</li><li>Gross margin rate improved 100 bps to 15.4%, driven by revenue mix, pricing and Motorhome segment operational improvements.</li><li>Operating margin rate decreased 80 bps to 6.7%.</li><li>Adjusted EBITDA dropped 12.4% to $34.49M.</li><li>Total motorhome deliveries down 17.4% Y/Y to 1,825.</li><li>Total towable deliveries squeezed 10.4% Y/Y to 7,596.</li><li>Dealer inventory: Motorhome -0.3% to 4,812; Towables +21.7% to 19,141.</li><li>The company expects tax rate to be ~22% for FY2019 and 23% to 24% for FY2020.</li><li>WGO <font color=\"green\">+0.31%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3445273-winnebago-eps-line-misses-revenue\" target=\"_blank\">Winnebago EPS in-line, misses on revenue</a> (March 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3445279\" data-linked=\"More Winnebago&#39;s Q2 results\" data-tweet=\"$WGO - More Winnebago&#39;s Q2 results https://seekingalpha.com/news/3445279-winnebagos-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3445279-winnebagos-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445278\" data-ts=\"1553513050\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTI\" target=\"_blank\">FTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445278-technipfmc-wins-integrated-epci-contract-from-eni-off-indonesia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TechnipFMC wins integrated EPCI contract from Eni off Indonesia</a></h4><ul><li>TechnipFMC (NYSE:<a href='https://seekingalpha.com/symbol/FTI' title='TechnipFMC plc'>FTI</a>) <font color=\"green\">+2%</font> pre-market after saying it was <a href=\"https://www.technipfmc.com/en/media/press-releases/2019/03/technipfmc-awarded-a-large-integrated-epci-iepci-contract-for-the-eni-merakes-field-offshore-indones\" target=\"_blank\">awarded a large contract</a> by Eni (NYSE:<a href='https://seekingalpha.com/symbol/E' title='Eni S.p.A.'>E</a>) for work on the deepwater Merakes project offshore Indonesia; FTI defines a \"large\" contract at $500M-$1B.</li><li>The contract covers five deepwater wells and their tie        back to the existing Jangkrik Floating Production Unit in Indonesia; project scope includes engineering, procurement, installation and        pre-commissioning of subsea equipment.</li><li>The fast-tracked field development <a href=\"https://www.upstreamonline.com/live/1737403/technipfmc-in-merakes-win\" target=\"_blank\">could be onstream by 2020</a> at a targeted production of 150M cf/day of natural gas.</li></ul><div class=\"tiny-share-widget\" data-id=\"3445278\" data-linked=\"TechnipFMC wins integrated EPCI contract from Eni off Indonesia\" data-tweet=\"$FTI $E - TechnipFMC wins integrated EPCI contract from Eni off Indonesia https://seekingalpha.com/news/3445278-technipfmc-wins-integrated-epci-contract-from-eni-off-indonesia?source=tweet\" data-url=\"https://seekingalpha.com/news/3445278-technipfmc-wins-integrated-epci-contract-from-eni-off-indonesia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3445260\" data-ts=\"1553508149\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMASY\" target=\"_blank\">IMASY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3445260-consortium-takes-inmarsat-private-for-3_4b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consortium takes Inmarsat private for $3.4B</a></h4><ul><li>It's going to take some deep pockets to challenge Richard Branson-backed OneWeb and Elon Musk's SpaceX (<a href='https://seekingalpha.com/symbol/SPACE' title='SpaceX'>SPACE</a>).</li><li>A group of private equity firms and pension funds have agreed to <a href=\"https://www.bloomberg.com/news/articles/2019-03-25/buyout-firms-pension-funds-to-buy-inmarsat-for-7-21-a-share\" target=\"_blank\">buy</a> Inmarsat (<a href='https://seekingalpha.com/symbol/IMASY' title='Inmarsat Plc'>OTCPK:IMASY</a>) for $3.4B, launching the U.K.-based satellite operator's shares <font color=\"green\">up 8.4%</font> in London.</li><li>The bidders - Apax Partners, Warburg Pincus, Canada Pension Plan Investment Board and Ontario Teachers\u2019 Pension Plan Board - were drawn to the \"considerable potential for in-flight connectivity and the internet of things,\" they said in a statement.</li><li>Related: ViaSat (NASDAQ:<a href='https://seekingalpha.com/symbol/VSAT' title='Viasat, Inc.'>VSAT</a>) and EchoStar (NASDAQ:<a href='https://seekingalpha.com/symbol/SATS' title='EchoStar Corporation'>SATS</a>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3445260\" data-linked=\"Consortium takes Inmarsat private for $3.4B\" data-tweet=\"$IMASY $SPACE $IMASY - Consortium takes Inmarsat private for $3.4B https://seekingalpha.com/news/3445260-consortium-takes-inmarsat-private-for-3_4b?source=tweet\" data-url=\"https://seekingalpha.com/news/3445260-consortium-takes-inmarsat-private-for-3_4b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":70,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}